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Nine commonly -isolated species of mycobacteria in 
Hong Kong including MycC?bacterium tuberculosis, 
Mycobacteri~m kansasii, Mycobacterium marinum, 
Mycobacterium scrofulaceum ; Mycobacterium _ gordonae, 
Mycobacterium avium-intracellulare complex, 
Mycobacterium terrae - complex, Mycobacterium fortui tum 
and Mycobacterium chelonae were first divided into three 
groups according to their growth rate and pigmentation, 
'followed , by discriminant analysis - on their 
saponification product profiles produced after gas 
liquid Chromatogra~ic analysis. All species except 
Mycobacterium scrofulaceum and Mycobacterium gordonae 
clustered well in the discriminant - analysis and were 
identified with _ an accuracy over 95%. A 100% accuracy 
was observed in separating Mycobacterium fortuitum, 
Mycobacterium chelonae and Mycobacterium tuberculosis. 
This - method was even useful in the sUb-species 
differentiation of Mycobacterium chelonae chelonae - and 
Mycobacterium chelonae abscessus with an accuracy over 
95%. 
In vitro 'susceptibility test of Mycobacterium 
tuberculosis isolates ~gainst all the common anti-
tuberculous drugs including streptomycin, isoniazid, 
r i f alllPicin ,ethambutol , ethionamide, pyraz inami-de, 
kanamycin I capreomycin I cycloser ine I ' ofloxacin ' and 
amik~cin have shown resistance ranging from o. 00% to 
-ii-
15.45%. More than 80% of the isolates were found to be 
. susceptible to all these drugs and 6% of the isolates 
(none of which originated from 'the pretreatment cases) 
resistant to more than ' 2 drugs. This low percentage of 
primary/initial resistance supports the notion that 
routine pre-treatment drug susceptibility tests for 
Mycobacterium tuberculosis are unnecessary. However, the 
discovery of multiple drug resistant isolates prompt the 
need to develop Et rapid screening system for them with a 
view to guide therapy appropriately. 
In contrast to -Mycobacterium tuberculosis, most 
atypical mycobacteria tested were found to be resistant. 
Moreover, different mycobacteria , species exhibit 
different drug susceptibi'li ty patterns; rapid and 
accurate identification before commencement of 
chemotherapy is mandatory in some cases. MIC25 , MIC50 
and MICgO of different drugs to different mycobacteria 
species tested were determined and the drugs of choice 
for treating different atypical mycobacterial infections 
are suggested. 
Plasmid was found to be universally present in the 
four Runyon's Groups of mycobacteria, and plasmids were 
- , 
first found in Mycobacterium gordonae, Mycobacterium 
terrae and Mycobacterium kansasii in this stuqy. 
Nevertheless, the · difficulties encountered in breaking 
mycobacterial cells render plasmid profile analysis of 
mycobacteria not completely satisfactory. Al though ' 
plasmid band was observed in a few 
tuberculosis isolates by using the 
procedure, further confirmatory tests 




could not be 
No corrlation 
between the plasmid profile and drug resistance or heavy 
metal (cadmium, lead and mercury) tolerance was observed 
among ' the atypical ' mycobacteria. Better cell breakage 
techiques have to be developed before plasmid profile 
analysis coul~ be fully applicable in the 
epidemiological sttidy of mycobacteria. 
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INTRODUCTION 
Tuberculosis has remained an important infectious 
disease in Hong Kong with annual notifications of 6500-
. , 
7000 in the last five years (H.K.OH. Report, 1989-90). 
Diseases caused by 'atypical' mycobacteria have also 
gained more attention in the last decade. The treatment 
of these mycobacterial in,fections is complicated and 
adequate support from the clinical laboratories is very 
important in combating the diseases. 
A clinical my~obacteriology laboratory has to serve 
four basic functions, viz isolation of mycobacteria from 
clinical specimens, id-entification of the clinical 
isolates, performing drug susceptibility test on the 
pathogens -isolated I and providing information for 
epidemiological studies. owing to the slow gro~th rate 
of most of the mycobacteria species and the complicated 
nature of identification and drug susceptibility testing 
scheme, 3-4 months are usually - required before a full 
laboratory report for mycobacteria investigation- is 
available, which might hamper the role of the laboratory 
services to subserve . the management of clinicians. 
Although there are rapid methods used in some countries, 
time consuming methods remain a practice in the clinical 
laboratories in Hong Kong . 
. since different mycobacteria species have different 
drug susceptibility patterns, the development of a rapid 
identification . scheme is extremely important. In · this 
study, fatty -acid analysis by gas liquid chromatography, 
1 
which . has been found useful in the identification of 
mycobacteria, was tested. for its species differentiation 
capacity and clinical applicability. 
suscep~ibility testing of anti-tuberculous drugs is 
another important task in a mycobacteriology laboratory, 
although its value in initial treatment cases of 
Mycobacterium tuberculosis infection and atypical 
mycobacterial infection have been questioned. In this 
study, commonly used anti -tuberculous drugs and some 
anti-microbial agents were tested for their acti~ities 
against different ;' mycobacteria species . . Percentage: 
resistance against currently used anti-tuberculous drugs 
and the drug susceptibility profiles of both 
pretreatment and retreatment cases of M.tuberculosis 
infections were investigated~ 
Epidemiological markers for mycobacteria are still 
under development. Plasmid identifications have been 
found useful as epidemiological marker in other 
bacteria and were first isolated in some mycobacteria 
species in the last decade. An attempt was made in this 
study to search for plasmids in different species of 
mycobacteria and, to investigate the usefulness on using 
plasmid as an epidemiological marker for drug resistance 
\ 
and/or heavy metal tolerance in mycobacteria. 
2 
Literature Review 
I. Mvcobacterial Infections 
A. Mycobacteria tuberculosis 
Tuberculosis is still an important infectious 
disease of high mortality and morbidity worldwide, with 
8 million new cases and 3 million mortality per year 
(Snider, 1988). In Hong Kong, despite advances in 
treatment and improved living conditions, the incidence 
as . revealed by the annual notifications rate has 
remained high ' i.e. 6500-7000 (H.K. DH Repo"rt, 1989-90) 
and the annual death rate has been around 7 per 100,000 
population in the last 5 years. Tuberculosis ranks the 
ninth amongst the most common cause of death in Hong 
Kong. 
B. Atypical mycobacteria 
Infections due to atypical mycobacteria which are 
usually opportunistic pathogens have gained more 
attention in the past d~cade (Covi, Velluti and Bisetti, 
1989, Wayne , and . Sramek, 1992). Species most commonly 
associated with diseases include M.avium-intrace11u1are 
complex (MAl), M .kan:sasii, M.marinum, M.fortuitum 
complex and M.ma1moense (Wolinsky, 1979) . They cause 
\ \ 
pulmonary diseases (Yeager and Raleigh, 1973; 
Rosenzweig, 1976; Lillo et a1 . , 1990; ' Tsukamura et aJ- · , 
1973; Awe, Gangadharam and Jenkins, 1973), disseminated 
diseases (Kiehn et al., 1985, saito et a1.,1974; Lillo 
et ai. , ', 1990), cervical adenitis (Marks et al., 1977), 
bone and joint diseases (Cheatum, Hudman and Jones, 
3 
1976; Godwin, 1965), skin and soft tissue diseases 
(Yamamoto et al'., 1970; Barrow and Hewitt, 1971; 
Subbarao, Tarpay and Marks, 1987; Juang et al.,1989)' , 
wound inf~ctions (Yew et aI, 1989; Jauregui, Arbulu and 
Wilson, 1977) and peritonitis (Selgas et al., 1987; 
Woods, Hall and Schreiber, 1986). Other species, 
including M.szulgai (Maloney et al., 1987; Medinger and 
Spagnolo, 1981), M.xenopi (Elston and Duffy, 1973; 
Tellis et al., 1977), M.simiae (Krasnow and Gross, 1975) 
and M~scrofulaceum (Gracey ' and Byrd, 1970)-, have been 
reported to be the aetiological agent of respiratory 
tract infections. Even the species usually considered as 
saprophytes such as M.gordonae, M.terrae, M.smegatis and 
M . thermoresistibile, have also been incriminated as 
pathogens under specific settings. Infections caused by 
these "saprophytes" were noted in the repiratory tract 
(Guarderas, Al varez and Berk, 1986 ; Douglas et al., 
1986; -Palmero, Teres and Eiguchi, 1989; Krisher, Kallay 
and Nolte, 1988), skin and soft tissue (McIntyre, 
Blacklock and McCormack, 1987, Wallace et al., 1988; 
Neeley and Denning,- 1989) and tendon sheal th 
(Karthigasu, Spagnolo and Gow, 1990; Petrini et al., 
1989) . 
Most of the atypical mycobacteria are resistant to 
the majority of 'anti-tuberculous drugs (Good, 1985) and 
to most of the anti-microbial agents (Davis et al., 
1987;. . Texier-Maugein et al.,1987). Unlike many other 
human pathogens, they also cause diseases in animals and 
4 
they can grow and survive under adverse conditions 
(Pelletier, Moulin and Stotmeier, 1988; Lockwood et al., 
1989; Klingeren and Pullen, 1987). The increasing 
incidence of atypical -mycobacterial infections, and the 
uncertainty of success in treating such infections have 
made them an extremely important subject - for study in 
the medical field (Covi, Velluti and Bisetti, 1989). 
II Identification of Mycobacteria 
Clinically, symptoms and radiologic findings from 
patients with pulmonary diseases ~aused by 
M.tuberculosis and atypical mycobacteria are 
indistinguishable (Hernandez et al., 1990; Lillo et al., 
1990; Maloney et al., 1987). Since different species 
give different drug susceptibility profile, (Guthertz et 
al., 1989, Sommers and Good, 1985), and treatment of 
tuberculosis and atypical mycobacterial infection should 
be guided, most of the time by species identification 
and drug susceptibilities (Tsukamura and Yamori, 1990), 
identification of mycobacteria is important for b6th 
diagnostic and therapeutic purposes. 
Traditionally, differential identification of 
mycobacteria is based upon the Runyon's scheme (Runyon, 
1959). The initial growping is based on pigment 
production and - growth rate, and · different batches of 
biochemical tests are then used for species 
differentiation within different groups (Sommers and 
Good, -_ 1985) .. Identification of mycobacteria in - the 
clinical la~oratory has remained a fastidious, difficult 
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and time-consuming procedure (Luquin et al., 1991). This 
is because of the slow growth rate of most species 
except the rapid growers, and the morphological, 
cultural and biochemical tests used for mycobacterial 
identification require ' specia-lized knowledge and well-
trained laboratory personnels (Sommer and Good, 
Tsukamura, 1981). To simplify or even replace 
1985; 
the 
complicated and time consuming procedure of the 
conventional identification methods, many investigators 
have devel 'oped quicker and . simplier _ techniques, 
including lipid c'omposi tion analysis (Welch, 1991; 
Jenkins, 1981), DNA · analysis (Sherman et al., 1989; . 
Rance et al., 1989) and protein analysis (Fourche et 
al., 1991, Verstijnen et al., 1991) of the mycobacteria. 
A. Conventional methods 
1. Mycobacterium tuberculosis 
conventionally M.tuberculosis is identified by its 
acid-fastness, slow growth rate, rough colonial 
morphology . and positive niacin test (Sommers and Good, 
1985). Other confirmatory properties are its ability to 
reduce nitrate, loss of catalase activity after being 
heated at 68 0 C (Runyon, 1970), resistance to 10 mglL 
thiophene-2-carboxylic a~idhydrazide (Wayne et al., 
1976) and susceptibility to sbo mg/Lp-nitrobenzoic acid 
(Tsukamura and Tsukamura, 1964; Barrie, 1967). 
The selective inhibition property of p-nitro-alpha-
acetylamino-beta-hydroxy-propiophenone (NAP) to 
M.tuberculosis ' and M.bovis in liquid media (Eidus, Diena 
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and Greenberg, 1959) was found to be very reliable in 
the identification of M.tuberculosis, with an accuracy 
of 99.5% (Laszlo and Edius, 1978). This test was found 
to be more reliable than the niacin test because some 
multiply drug resistant M.tuberculosis isolates had 
shown negative niacin reaction (Tsukamura, 1974) while 
no cross-resistance between the anti-tuberculous drugs 
and NAP was observed (Laszlo and Eidus, 1978). This NAP 
inhibition test was later employed in the BACTEC system 
for identification of M.tuberculosis (Anargyros, -Astill 
and Lim, 1990; Laszlo and Siddiqi, 1984). 
2. Atypical mycobacteria 
After Runyon (1959) proposed the classification 
schemes for atypical mycobacteria, some essential 
characteristics such as Tween 80 hydrolysis (Wayne, 
Doubek and Russell, 1964), tellurite reduction (Kilburn, 
silcox and Kubica, 1967), arylsulphatase activity 
(Tarshis, 1963), urease activity (Pawlicki, Hertz and 
Green, 1962), deamidase activity (Cerbon and Trujillo, 
1962), catalase activity (Csillag, 1961), optimal growth 
temperature . (Csillag, 1961) and the utilization of 
nitrogen sourc~s (Tsukamura and Tsukamura, 1965; 
Tsukamura, 1964) and carbon sources (Tsukamura, 1965), 
were investigated for their ·values in species 
differentiation. Practically, tests that are easy to 
perform, with diagnostic value and high degree of 
reliability are selected nowadays for diagnoistic uses 
. (Sommers and Good, 1985). 
7 . 
The Adansonian classification of numerical taxonomy 
which awards equal weight to all available characters 
and arranges all strains into a sequence of high 
~imilarity to , low similarity (Wayne, 1981), has also 
been used by some investigators for the sorting of 
mycobacteria into clusters with high degrees of internal 
similarity within each Runyon group (Wayne, Doubek and 
Diaz, 1966; Wayne, 1965; Tsukamura, Mizuno and 
Tsukamura, 1968). This classification method is 
obj ecti ve and is very useful in the taxonomical study 
~ , 
(Wayne, 1981) .Howe~er, since it requires a large number 
of characteristics for identification, this scheme is 
laborious and time consuming, and is therefore beyond 
the scope of most diagnostic laboratories (Kubica, 
1973) . 
B. Rapid identification methods 
1. Identification by fatty acid analysis 
Lipid analysis have been proven useful in the 
classification and identification of mycobacteria as the 
differences in lipid composition have been shown to 
provide a tool for di~tinguishing mycobacteria from 
related taxa and' also for differentiation of species 
within this genus (Welch, 1991). Analysis of the 
cellular fatty acids by gas-liquid chromatography (GLC) 
has been reported to be a particularly suitable method 
for the identification of mycobacteria because of its 
simpl~city and capacity of distinguishing between 
closely related species ( Tisdall, Roberts and Anhalt, 
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1979; Valero-Guillen, Pacheco and Martin-Luengo, 1985) 8 
A tree structure identification scheme for 18 
mycobacterial species has been ' developed based on their 
relative amount of extracted fatty acids analysed by GLC 
(Tisdall Roberts and Anhalt, ~979). When the scheme was 
applied to analyse a series of 335 isolates, 67% were 
correctly identified and a further 28% were reliably 
grouped with an analysis time of as little as 1.5 hours. 
When the same scheme was put to a routine laboratory 
(Tisdall et al. J 1982) identification of mycobacteria by 
GLC and convention'al biochemical methods gave a total 
. agreement of over 95%. Similar results were obtained 
when the scheme was verified later by Mayall (1985). 
2.Identification by mycolic acid analysis 
Guerrant, Lambert and Moss (1981) reported when the 
fatty acid methyl esters extracted from mycobacteria 
were analyzed at high injector temperature (300-350 oC), 
characteristic thermal cleavage products (C 22 : 0" 
C24 : O' C26 : 0 ) of mycolic acids could be detected, ·and 
the abundance of these cleavage products could be used 
for identification of mycobacteria. They also pointed 
out that two k'ey fatty acid esters in the Tisdall 
identif ication scheme (\1979) were or igina ted from 
mycolic acid because high injector temperature (27SoC) 
were .used. However,the ability to obtain mycolic acid 
cleavage products, varies greatly from laboratory to 
labor~tory (Guerrant, Lambert and Moss,19B1; Lambert et 
al., 1986; Larsson, Jantzen and Johnsson, 1985), and 
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standardization of culture medium, hydrolysis 
procedures, as well as GLCrunning conditions have to be 
made before reproduciable resul ts can be obtained 
(Larsson, Jantzen and Johnsson, 1985). 
Mycolic acid pattern determined by thin layer 
chromatography (TLC) was also found useful in the 
identification of mycobacteria (Marks and Szulga, 1965; 
Jenkins, 1981). This was particularly so in the 
differentiation of M .malmoense and M. simiae from MAr 
' (Levy-Frebault, Goh and David, 1986; Valero-Guillen et 
al., 1988) and in cl'istinguishing among various species; 
of rapidly growing mycobacteria (Damato, Knisley and 
Collin, 1987; Valero-Guillen and Martin-Luengo, 1983; 
Levy-Frebault et al., 1983; Minnikin et al., 1984). 
However, this procedure wa's only recommended as a 
supplementary rather than a routine identificatioh 
procedure' in clinical or even reference laboratories 
because the procedure is complicated (Jenkins, 1981), 
and artefacts may be introduced during the preparation 
of mycolate lysates (Valero-Guillen, Pacheco and Martin~ 
Luengo, 1985). 
High perfor~ance l 'iquid chromatography (HPLC) has 
also been applied to analyse the p-bromophenacyl ester 
- \ 
of mycolic acid in mycobacteria (Butler, Ahearn and 
Kilburn, 1986; Butler and Kilburn, 1988; 1990) and the 
preliminary results showed that this method was useful 
in the differentiation of certain mycobacterial species 
including M.tuberculosis, M.avium, M.kansasii, 
M.gordonae, M.intracellulare (Butler and Kilburn, 1988), 
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M.che1onae, M.fortuitum, and M .smegatis (Butler and 
Kilburn, 1990). More work have to be done before this 
method can be clinically applicable not to mention the 
lack of a~ailability commerically of the mycolic acid 
standards (Butler and Kilburn, 1988). 
III In vitro Susceptibility Testing of Mycobacteria 
·A. Mycobacterium tuberculosis 
The slow growth rate of M. tubercuo1sis makes the 
drug susceptibility test complicated and labour 
intensive. The con~enient disk diffusion method cannot 
be applied to M. tuberculosis and the general accepted 
methods are based on the growth of the organism on drug 
containing media. Much precaution has to be taken in 
performing the test because various technical errors 
including irregular heating and storage of medium 
(Sabol1a et al., 1983), interaction between drug and 
culture medium ingredients (Gangadharam, 1970; Guthertz 
et al., 1988) and unsuitable controls (Marks, 1961) can 
affect the result. Transitional resistance lack of 
standardisation of inocula, incubation, result reading 
and interpretat~on (Ml'tchison, 1968), can also prove 
disturbing as regards the validity of the test. 
\ . 
Several functions of drug susceptibility test on 
M.tuberculosis have been proposed (Canetti et al., 1963; 
Mitchison, 1968, Canetti, et al., 1969) .• J Firstly, the 
susceptibility test can be used as a 'guidance in the 
choice of chemotherapy given to the patient. Secondly, 
it may be of value in confirming that drug resistance 
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has emerged when a patient has failed to show a 
satisfactory clinical response judging by failure of 
smear or culture conversion, and may guide revision of 
the treatment regimen. Thirdly, it may be used to 
estimate the prevalence of primary/initial and acquired 
drug resistance which is important in planning 
community-bases chemotherapy programmes (Riley, Arathoon 
and Loverde, 1989; steiner et al., 1985). Lastly, it can 
help in the scientific research on mechanisms of drug 
. action · and in the :, development of . new antt-tuberculous· · 
drugs (Roffner et al., 1990; Wong, Palmer and Cynamon, 
1988; Hoffner and Kallenius, 1988; Casal et al., 1987; 
Heifets et al., 1985; Cynamon and Palmer, 1983). 
1. Principle : 
Clinically, M. tuberculosis strains which are not 
inhibited by the drug concentration rea~hing the site of 
infection are termed resistant (Canetti et al., 1969). 
In bacteriological sense, resistance can be defined as a 
decrease in susceptibility of sufficient degree to allow 
reasonable certainty that the strain concerned is 
different from ~ sampl'e of wild strains of human type 
that have never come into contact with the drug (Canetti -
" \ 
et al., 1963). For most of the anti-tuberculous drugs, 
there is evidence that a diminished clinical response 
may .occur when resistance in the a.bove-mentioned 
bacteriological sense is demonstrated in the laboratory 
(Canetti et al., 1969). 
Every wild strain of M. tuberculosis contains some 
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mutants resistant to anti-tuberculous drugs. The 
difference between a resistant strain and a sensitive 
strain is that the proportion of resistant bacteria is 
much higher in a resistant strain than in a sensitive 
one (Canetti et al., 1963). ' If 1% or ,more of the 
bacterial population is resistant to a critical drug 
level , in vitro, the drug will be ineffective in vivo 
(Canetti et al., 1963). 
2. Methods of susceptibilty testing 
Conventionally, there are three laboratory methods , 
for drug susceptibility test , on M. tuberculosis. They 
are the absolute concentration method, the resistance 
ratio method and the 1% proportion method (Canetti et 
al.,1963i Canetti et al., 1969). All the procedures 
require 3 to 4 weeks before the results are available, 
and none of them shows a clear scientific superiority 
over the others. As a result, the method chosen by any 
researcher remains a matter of personal preference only· 
,(Montalbine and Collins, 1971) . Recently, rapid 
susceptibility testing ~ethods have been developed for ' 
shortening of the reporting time . These include the 
radiometric method (Vincke et al., 1982; Anargros, 
Astill and Lim , 1990), b~qluminescence method (Nilsson, 
Hoffner and Ansahn, 1988) and gene-probe 
hybridization method (Kawa et al., 1989). 
a. The absolute concentration method (Canette et 
al .. ,1963) 
DNA 
The absoulte concentration method consists of 
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determining the minimum inhibition concentration (MIC) 
of each drug against th~ test strain. When the MIC is 
above a pre-determined critical concentration (break 
point), the strain is classified as resistant; below, as 
sensitive. critical MIC "of each drug was determined by a 
drug resistance survey in which a series of strains from 
pre-treatment cases were cultured simultaneously with 
the control strains from retreatment cases. critical MIC 
was the concentration that distinguish most the 
pretreatment from the re-treatment one. 
since the MIC obtained depends on a number of 
factors including the types of culture medium, details 
of medium preparation, methods of preparing inoculum, 
inoculum size, air supply to the medium during 
incubation and the incubation period, the critical MIC 
of a drug in one laboratory may be different from 
another, even though apparently similar techniques are 
used. Techniques may also change over a long period in 
the same laboratory and " thus, "it is necessary to review 
the critical Mrcs at regular interval. 
The culture medium used in the absolute 
concentration method 'is the Lowenstein-Jensen (LJ) 
medium. "Uniform drug concentration has " to be prepared 
., \ 
and checked carefully in each new batch of media. with a 
standard MRC inoculum (2000 - 10000 colony forming units 
(CFU)], less than 20 isolated colonies on the drug 
containing slope is considered as sensitive. 
This test is technically simple and easy to perform 
in a routine mycobacteriology laboratory. Since there is 
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no need to estimate the actual proportion of resistant 
strains in the population, this method is less 
influenced by the clumping effect of the acid fast 
bacilli. 'Moreover, as pre-treatment drug resistance 
survey has to be conducted at regular interval, a better 
in vitro ans in vivo correlation can be obtained. The 
most obvious limitations of using this method are 
variability of the inoculum size and the standardization 
of the drug-containing medium. since standard inoculum 
is us~ally obtained subjectively by the~ naked eyes 
(objective method is not available), variations always 
occur among individual tests. Inactivation of drug in 
the LJ medium cannot be ignored. Although this has been 
taken into account in determining the critical 
concentration, it is still impossible to standardize the 
extent of inactivation even within the same batch of 
media. Moreover, this method is practical only when 
centralized mycobacteriology laboratory service has been 
developed in a community because surveys have to ' be 
conducted in every laboratory before the critical 
concentration for each drug can be determined. 
b. The resistance ratio method (Canette et al., 1963; 
Mitchison, 1968) \ 
The test procedure and medium used is similar to 
those in the absolute concentration method except a 
control strain,namely H37Rv, is included in each test 
batch ' as an internal standard. 'For every drug tested, 
the ratio of MIC of the test strain to MIC of H37Rv is 
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calculated and termed as the 'resistance ratio' (RR). A 
test strain is considered 'sensitive' to a drug if its 
RR is 1 or 2, and 'resistant' when its RR is 8 or above. 
When the ' value of RR is 4, repetition of the 
susceptibility testing is suggested. 
Variation in techniques among batches willequall~ 
affect both the test and control using this method/and 
therefore will not affect the result. Moreover, because 
of the built-in standardization, results are more stable 
than those in the absolute concentration 1nethodwhen 
comparsions were made between laboratories (Mi tchison, 
1968). However, this method may not be appl icable to 
every anti-tuberculous drugs. In second line drugs such 
as ethambutol and ethionamide, the critical ratio that 
distinguishes sensitive and resistant strains usually 
lies between 2 and 4. When using a serial 2-fold drug 
dilution, the result appears to be unsatisfactory. In 
addition, the control strain H37Rv imposes another 
source of error. Since this strain was isolated about 80 
years ago (Mark, 1961), its sensitivity may not be the 
same as the mean sensitivity of a sample of currently 
isolated wild strains. There was evidence that different 
sub-strains of H37Rv rnigh~ occasionally vary in their 
sensitivities (Mark, 1961). 
c. The 1% proportion method : 
The 1% proportion method consists of calculating 
the proportion of resistant bacilli present in a strain. 
Two appropriate bacillary dilutions, a high and a low 
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one, are inoculated on drug-containing and drug-free 
medium. The ratio of the number of colonies obtained on 
. the drug-containing medium to the nurnber of colonies 
obtained on the drug-free medium indicates the 
proportion of resistant bacilli present in the strain. 
Below a certain proportion, usually 1% , the strain is 
6lassified as sensitive; above, as resistant. 
Middlebrook 7H10 or 7H11 agar wi th 10% oleic 
albumin dextrose catalase (OADC) (Difco) enrichment was 
used to make the basal medium~ Drug~ could be 
incorporated into the media by commerically available 
inpregnat'ed ' paper disks (Wayne and Krasnow, ' 1966; 
Griffith et al., 1967). After inoculation, each plate 
was sealed in a polyethylene bag and incubated under 5% 
carbon dioxide at 35-37oC for 3 weeks before the result 
were interpretated (Vestal, 1975). 
Several advantages are 
proportional method. It is 
observed in using the 
much easier to perform 
because both th~ . medium preparation and the inoculating 
procedures are technically simpler and less tedious. 
without inspissation, inactivation of drugs can be kept 
minimal ( Sabolla et al., 1983) • This method by 
principle can provide a more accurate estimation of the 
relative proportion of sensitive and resistant organisms 
in an , isolate, and is independent to the effect 6f 
inoculum size. Moreover, the same definition of 
resistance ,. can be used for both indirect and direct 
tests and no , adjustment on interpretation of results is 
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required. However, clumping of bacilli can directly 
affect the result. Although large clumps can be avoided 
by using various dispersing techniques, effect of small 
clum~s should not be ignored (Mitchison, 1968). Unlike 
the two above methods, petri dtshes are used instead of 
screw cap bottles. This engenders a greater risk for th~ 
laboratory staff. Since wild strains are not required in 
thi~ test as reference, careful standardization is 
needed in the transfer of technique among laboratories 
(Mitchison, 1968) .. 
d. Radiometric method 
Radiometr ic method . is based on the measurement of 
14CO liberated from the oxidation of 14C-labelled-2 
palmitate by the organism. Production of 14CO 2 is 
quantitatively decreased in the presence of drugs that 
inhibit the organism (Siddiqu, Libonate and Middlebrook, 
1981; Tarrand and Groschel, 1985). The definition of 
resistance is based on the proportional method where 1% 
production of 14CO 2 was used as the cri teriaof 
resistance. BACTEC system, a commerically available 
. radiometric system has allowed wide applicability in 
many laboratories' (Laszlo et al ~, 1983; Laszlo, 1985). 
Anti-tuberculous drugs cUlrrently available for testing 
- include streptomycin, isoniazid, rifampicin and 
ethambutol. Test on pyrazidamide is still under 
investigation after preliminary studies (Woddley and 
smithwick, 1988; Tarrand spicer and Groschel, 1986; 
Heifets and Iseman, 1985). Roberts et al. (1983) 
18 
compared the BACTEC system with the 1% proportion method 
and found a 90 to 100% agreement with an average 
reporting time of 4.2 to 6.9 days. Fadda and Roe (1984) 
reported similar correlation in studying M.tuberculosis 
isolated from extra-pulmonary sources. Anargros and 
assoicates (1990) found that the susceptibility test 
results of 18 M.tuberculosis isolates from BACTEC agreed 
comp~etely with those obtained by the resistance ratio 
method. Tarrand and Groschel (1985) even demonstrated a 
better precision and accuracy on the radiometric method 
than ~he proportional plate method when artificial : 
mixtures of 1% resistant and 99% sensitive 
M . tuberculosis strains were tested. Direct test has 
also been performed with satisfactory results (Libonati 
et al., 1988). 
Disadvantages of this method include its expensive 
running costs (Presslich, Lahounik ·· and Kraus, 1989) and 
inaccuracy on testing certain drugs as large scale 
comparative studies revealed that the agreement between 
TB-BA.CTEC with standard methology was less satisfactory 
with drug-resistant strains (Snider et aL., 1981), 
especially on streptomycin (Siddiqi, Libonati and 
Middlebrook, 1981) and ethambutol (Laszlo, 1985) . 
. , , 
e.other methcds 
R~cently, Kawa et al. (1989) demonstrated that the 
use of the Gene-probe DNA Hybridization System in 
performing susceptibility test to isoniazid was rapid 
and ' specific. , The preliminary studies on susceptibility 
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to common anti-tuberculous drugs using bioluminescence 
assay of mycobacterial adenosine-triphosphate (ATPi) 
(Nilsson, Hoffner and Ansahn, 1988) showed that the test 
was rapid. with results seemingly comparable to the 
conventional method (Beckers ,et al., 1985) . . Further 
evaluation is necessary before these tests can be 
utilised to a routine clinical laboratory. 
B. Atypical mycobacteria 
In the sense of drug susceptibility, atypical 
mycoba.'cteria · is a group of multiply drug-resistant and 
heterogenous organisms (Hugo, 1981) Unlike 
M • tuberculosis, there is no standard method in 
performing the susceptibility test in vi tro (Heifets, 
1988). Various methods have been employed by different 
investigators, including the broth dilution method 
(Arai, Nakajima and Kaminaga, 1990; Inderlied, Young and 
Yamada, 1987), the agar dilution method (Casal, 
Rodriguez and Benavente, 1985), the microdilution method ' 
(Yajko; Nassos and Hadley , 1987; Swenson, Thornsberry 
and silcox, 1982), the radiometric method (Heifets, 
1988; Trimble et al., 1987), the proportional method 
(Demoulin, Medard ' and Kellens, 1983; Salifinger, Hohl 
and Kafader, 1988; Kantor) Barrena and Lunardo, 1985) 
and the disk diffusion method ' (Wallace, Dalovisio and 
Pankey, 1979; Casal and Rodriguez, 1981; Orefici and 
Scopetti, 1983). 
Although certain regimens for treatment · of 
infection caused by some atypical mycobacteria have been 
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recommended (Tsukamura and Yamori, 1990), susceptibility 
tests on clinical isolates are important because 
variations in the susceptibilities within species have 
been studied and confirmed in many atypical 
mycobacterial species (SwensoI}. et al., 1985; Neubert, 
1986; Yajko et al., 1988; Covi, Velluti and Bisetti" 
1989). Horsburgh and associates (1987) studied the 
responses of chemotherapy on 75 patients ,wi th MAl 
pulmonary infections, and found that the responders 
received significantly more drugs , to which their MAl , 
isolates were serisitive in vitro than did non-
responders. Another study ' on 123 patients with non-
pulmonary ' infection due to M. fortui tum or M. chelonae 
treated on the basis of in vi tro susceptibility tests 
showed that relapses were rare (Wallace et al., 1985a). 
Suscessful treatment of M. chelonae pulmonary infection 
with one , drug based on disk ' diffusion susceptibility 
data has also been reported (Irwin et al., 1982). All 
these studies shared 'the same view that in ' vitro 
susceptibility tests on atypical mycobact'eria are 
clinically useful. 
On the contrary, many studies showed that the 
results of the in vitro drug susceptibility test borne 
.\ 
little relation to the clinical response observed when 
these drugs were used for treatment (Hunter et al., 
1981, Banks et 'al., 1984, Rauscher, Ke.rby and Ruth, 
1974). Cycloserine and ethionamide, though exhibiting 
favourable in vitro aans in vivo activity have poor 
patient acce'ptance due to high drug toxicity (Hunter et 
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al., 1981; Banks et al., 1984; Banks, Jenkins and Smith, 
1985). Paradoxically, · sucessful treatment on MAl has 
been . achieved with combinations of standard anti-
tuberculous agents though the in vi tro results showed 
that these isolates were resistant (Hunter et al., 1981; 
Engbaek, Vergmann and Bentzon, 1984; France et al., 
1987) . 
Such discrepancy between in vitro and in vivo 
outcome probably result from lack of standardisation of 
methology in susceptibility testing (Inderlied, · Young · 
and Yamada, 1987), limited understanding of drug 
behaviour in vitro (Heifet, 1988) and in vivo (Banks, 
1989). Obviously, much efforts have to put into this 
area in order to make the laboratory ~esults useful to 
the clinicians for the treatment of the diseases caused 
by atypical mycobacteria. 
IV Plasmid Analysis in Mycobacteria 
A. Discovery of plasmids in mycobacteria 
Plasmids in mycobacteria were first isolated in 
1979 from M. avium-intracellulare complex (Crawford and 
Bates, 1979). In ,this discovery, 9 out of 20 M.avium-
intracellulare complex strains were found to contain 
.\ 
plasmid(s) by agarose gel electrophoresis. Two plasmid 
bands . found in the wild strain (LR25) were confirmed as 
covalently closed 'circular DNA by cesium chloride 
(CsCl)/ethidium bromide gradient ultracentrifugation. 
The pl~smids were subsequently characterized by electron 
microscopy to have molecular weights ranging from 
22 
10.7xl06 to 107x106 . (Crawford, Cave and Bates, 1981). 
The presence of plasmids were also reported in 
other atypical mycobacteria including M.scorfulaceum 
(Meissner ' and Falkinham, 1984; Erardi Failla and 
Falkinham, 1987), M.foruitum (Wallace et al. ,1984; Hull 
et al., 1984),1 M. chelonae (Wallace et al., 1985) and 
M~smegmatis (Norgard and Imaeda,1980). However, plasmid 
was not found in M.tuberculosis. About 200 
M . tuberculosis clinical isolates were screened by 
zainuddin and Dale (1990) .for the presence ~~of plasmid. ' 
They were able to detect bands of apparently 
extrachromosomal DNA at a low level in some isolates by 
gel ~lectrophoreis. Nevertheless, these presumptive 
plasmids could not be isolated by CsCI/ethidium bromide 
gradient ultracentrifugation. 
B. Methodologies in the studies of mycobacterial 
plasmids 
The' major obstacle to the isolation of DNA from 
mycobacteria is the lack of a . gentle cell lysing 
procedu~e. Most mycobacterial strains were resistant to 
lysozyme and were not lysed by 4% sodium dodecylsulphate 
(SDS) at 60 0 C (Cr'awford and Bates,1979). In order to 
make the cells sensitive to lysozyme and SDS, the cells 
were either first treated ' with cycloserine and 
ampicillin (Franzblau, Takeda and Nakamura, 1986;' 
Crawford and Bates, 1986 ) or treated wi th glycine 
(Zainuddin and Dale, 1990, Hull et al, 1984; ' Mizuguchi, 
Fukunaga and Taniguchi, 1981) for 24 to 48 hours at 37 0 C 
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before SDS treatment. After SDS treatment, the 
procedures first reported by Kado and Liu (1981) 
(Meissner and Falkinham, 1986; Crawford and Bate, 1986), 
salt precipitation (Sheila et aI, 1984, Crawford and 
Bates, 1979) , or sodium _perchlorate treatment 
(Mizuguchi, Fukunaga and Taniguchi, 1981) were employed 
for the isolation of plasmids from the SDS lysate. 
C. possible roles of plasmid in mycobacteria 
epidemiology 
Plasmids have been demonstrated in many bacteria 
and found to carry genes for a variety of functions 
(E79. specific drug resistance, heavy metal resistance) 
which are very important in epidemiological studies. 
since plasmids are also common in some clinical isolates 
of mycobacteria and are stable during culture and 
exposure to sodium hydroxide treatment, plasmid analysis 
appearst6· be a suitable epidemiological tool (Meissner 
and Falkinham, 1986). Plasmid analysis had been used in 
the investigation of the source of rapid growing 
mycobacteria causing infections after cardiac surgery 
(Wallace et al .. , 1989a) and augmentation mammoplasty 
(Wallace et al. 1989). 
A few functions of mycobacterial plasmids have been 
\ 
reported. These include transparent-to-opaque colony 
morphologic variation in M.intracellulare (Mizuguchi, 
Fukunaga and Taniguchi, 1981) , DNA . restriction 
medif ication in M. avium intracellare complex (MA!) 
(Crawford et al., 1981), mercury resistance via mercuric 
reductase activity ( Meissner and Falkinham, 1984) and 
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copper resistance (Erardi, Failla and Falkinham, 1987) 
in M. scrofulaceum. However, only one s·train was studied 
in each incidence. Although the results were not 
definite, a possible role of plasmid in the virulence of 
MAl strains has also been suggested (Gangadharam et al., 
1988), but the results were not definite. 
Relationship between plasmid prof ile and drug 
resistance has been investigated but with disappointing 
results. In a study on M.fortuitum and M.chelonae, · 
. plasmids of several size were found " in ~ both drug-
susceptible and resistant isolates, and acquired 
resistance was not associated with change in the 
apparent size or number of the plasmids (Wallace et al., 
1985) . . Another study on 25 MAl strains showed no 
relationship between plasmid contents and drug 
:r~sistance (Masaki et al., 1989).' Undoubtedly, more work 
needs to be done on the elucidation of the functions 
coded by the plasmids in mycobacteria so that they can -
serve as epidemiological markers. 
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MATHERIALS AND METHODS 
I. Bacterial strains and strain Maintenance 
A. strains collection 
All ciinical isolates of mycobacteria were generous 
gifts of the Hong Kong Reference Mycobacteriology 
Laboratory in Yung Fung Shee Memorial ' Centre (YFSMC). 
Reference strains of . M. tuberculosis and other 
mycobacteria species were purchased from the Trudeau 
Mycobacterial Collection ' (TMC), American Type Culture 
Collection (ATCC) and National Type Cultur€ Collection 
(NTCC) (Table 1). 
B. strain maintenance 
All isolates were maintained in 1. 0 ml 7H9 broth 
(Difco) supplemented with 1'0% oleic acid dextrose 
catalase (OADC) (Difco), and stored at -70o C. 
II. culture Media and Culture Condition 
AII- bacterial isolates were normally grown on 
Lowenstein Jensen medium at 35 to 37 0 C aerobically:. _ 
Middlebrook 7H9 broth containing 0.05% Tween 80 (Sigma) 
and 10% OADC were empl~yed for cUltivation prior to 
plasmid extractiori procedures. Middlebrook 7H10 agar 
(Difco) supplemented with 1'0% OADC was used as the basal 
medium for the heavy metal tolerance - test. 
Ill. Identification of Mycobacteria 
A. Conventional methods 
All mycobacteria studied, including the standard 
strains and the clinical isolates, . were identified by 
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their growth rate', colonial morphology, pigmentation and 
biochemical properties, using standard procedures 
(Sommers and Good, 1985). Slowly growing species were 
tested for niacin, . urease, semiquantitative and heat-
stable catalases , nitrate and telluri te reduction . as 
well as Tween 80 hydrolysis while the . rapidly growing 
species were studied for 3-days arylsulphatase, nitrate 
reduction, . tolerance to 5% NaCl on Lowenstein Jensen 
medium and growth on MacConkey agar and nutrient agar. 
B. Fatty acid profil~ analysis 
1. Bacterial isolates 
Mycobacteria,including M.tuberculosis, M.kansasii 
, M.gordonae M.scrofulaceum ,M. terrae, M. avium 
intracellulare complex (MAr) , M.fortuitum and 
M.chelonae were selected among the clinical isolates in 
YFSMC from 1988 to 1991. The sample size of each species 
studied ranged from 4 to 42 for gas chromatograph-mass 
. spectrometry (GC-MS) (Table 2) and 1 to 31 for gas 
liquid chromatography (GLC) (Table 3) such that a 
significant statistical analysis could be achieved. 
standard strains used "were M. tuberculosis (H37Rv) , 
M.kansasii (ATCC 12478), M.marinum (ATCC927), M.simiae 
\ 
(ATCC 25275), M.flavescens (ATCC 14474), M.avium (ATCC 
13950, TMC 724), M.chelonae (ATCC 14472), M.fortuitum 
(ATCC 6841, TMC 1323), M.chitae (ATCC . ·19 627) , and 
M.diernhoferi (ATCC 19340). 
2. Staridards and reagents 
The authentic standard methyl esters of fatty acid 
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(Table 4) were purchased from Sigma (st. Lotus) and the 
synthesized racemic tuberculostearic acid (TBSA) was 
donated by Drs.L.Larsson and G.Odham (University of 
Lund, Lun'd, Sweden). Sodium hydroxide pellets (NaOH) 
(sigma), methanol (BDH) , chlorof6rm (Riedel de Haen) , n-
hexane (Riedel de Haen) , boron trichloride/methanol 
(10%; Sigma), and hydrochloric acid (HCI) (Riedal de 
Haen) were all of reagent grade and were used without 
further purification. 
3. Preparation of methyl ester for GC/GC-MS 
-, 
Mycobacterial cells (5-10 mg) were suspended in a 
minimal volume of distilled water (approx. 0.5 ml) in a 
reaction vial (capacity, 10.0 ml). Four millilitres of 
5% (w/v) NaOH in methanol-water (1:1 [v/v]) was added. 
The mixture was then heated at 100 0 C for 30 minutes, 
cooled, acidified to pH 2.0 with 6.0 N HCI, and 
extracted by a mixture of chloroform-hexane (1:4 [v/v]). 
The extracts were dried under a stream of dry nitrogen. 
The dried extracts were then reacted with 4.0 ml of 10% 
boron trichloride/methanol for 30 minutes at 100o C, 
cooled and re-extracted by using chloroform-hexane. The 
extracts were dried under nitrogen and redissolved in 
\ 
minimal volume of methanol, and 1 ul was injected with a 
Hamilton syringe into the gas chromatograph for 
analysis. 
4. Instrumentation 
a. Gas chromatography - mass spectrometry (GC-MS) 
The GC-MS equipment was manufactured by Hewlett-
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Packard (AvondaleiCalif). · A quadrupole mass selective 
detector (model HP 5970A) coupled to a gas chromatograph 
(model HP 5880A) was used. The system was controlled by 
a desktop computer (model HP 9825B) linked to a 
Winchester disk drive (model HP 9134A) with 4.6 
megabytes of ·· storage capacity. The chromatograms and 
spectra were printed with a graphics printer (model HP 
2671G). The chromatographic column used was a 25-m high-
performance capillary column of cross-linked 
methylsili.cone (OV-l) with an ·internal diam-eter of 0.2 
mm and a film thickness of 0.33 urn (Hewlett-Packard). 
The injector port temperature and the interface 
temperature were set at 260oC. The oven temperature 
started at 110o C, with an initial assay time of 3 
minutes, and then increased at a rate of 6oC/min. to a 
final temperature of 260°C, which was maintained for 10 
minutes. The mass selective detector was operated under 
a vaccum- of 1.5x10-5 torr, and the analyzer temperature 
was at 200oC. Peaks were recorded ~f not less than 1% of · 
the ions detected were with a mass/charge ratio (rn/e) of 
74. 
b. Gas liquid chromatography (GLC) 
The gas chromatogr~ph (model HP 5890A) was 
manufactured by Hewlett-Packard (Avondale,Calif) with a 
built in flame ionization detector. The chromatograms 
and spectra were printed with an integrator (HP 3392). 
The chromatographic colu~n and its running condition was 
. identical to the setting in GC-MS analysis. 
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5. Fatty acid profile analysis 
a. Calibration 
About lug of the ten authentic fatty acid methyl 
ester standards (Table 4,5) were injected into both the 
GC-MS and GC to obtain their corresponding retention 
time. Moreover, mass spectra of these standards obtained 
from the GC-MS · were used in the construction of the 
reference library. 
b. Identification of mycobacterial fatty acids 
All the peaks eluted in the mass chromatogram of 
GC-MS analysis of the mycobacterial fatty acid extracts 
were identified by their relative retention times and 
mass spectra in comparsion with those of the authentic 
standards. If a standard was ' missing for a particular 
peak, peak identity was determined by its mass spectrum. 
Similar fatty acid peaks eluted from GLC analysis (Table 
5) were identified by relative retention time in 
comparsion with the profile produced by the GC-MS 
analysis. 
c. Construction of mycobacterial fatty acid profile 
Fatty acids ,with retention time between 10 to 38 
minutes were detected. In the GC-MS analysis, the 
'\ 
abundance of each fatty acid was calculated from 
summation of the output (TOTAL ABUNT) generated under 
each peak as printed in the spectral plot (Figure 1). In 
GLC, the fatty acid abundances were integrated 
mathematically as area under the peak expressed by the 
FID output (Figure 2). The relative percentage of each 
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peak was then calculated and was used for statistical 
analysis. 
6. Discriminant analysis 
Discriminant analysis of t~e fatty acid profiles 
was performed by SPSSjPC, an IBM PCjXTjAT computer 
software package purchased from SPSS Inc. (Chicago). 
Prior to discriminant analysis, all clinical 
isolates were identified to species level by 
conventional methods. ·All. species were divided into 3 
groups . according to their growth rate and pigmentation 
(Table 6). 
IV. In vitro Drug Susceptibility Test 
A. Test strains 
Three hundred and ninety seven M. tuberculosis 
isolates 'and one hundred and five 'atypical 
Mycobacteria' isolates were studied. out of the 397 
M.tuberculosis isolates, 369 were the routine clinical 
isolates 'from YFSMC in January, 1989 and the' remaining 28 
were selected 'resistant isolates. The 'atypical 
mycobacteria' were collected between July,1988 and 
December,1988 in YFSMC together with randomly selected 
isolates of M .kansasii, f.l~marinum and M. scrofulaceum 
(Table - 7) . Standard strains used were M. tuberculosis 
(H37Rv), M.marinum (TMC 1218, ATCC 927), M.kansasii (TMC 
1201, ATCC 12478), M.scrofulaceum (ATCC 19981), M.avium 
(TMC 72.4, ' ATCC 13950) and M .fortuitum (TMC 1323, ATCC 
6841), . 
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B. Prepatarion of drug~containing media 
sixteen drugs were tested. Isoniazid, ethambutol 
hydrochloride, kanamycin sulphate, capreomycin sulphate, 
D-cycloserine, pyrazinamide and streptomycin sulphate 
were dissolved in distilled water-. Ofloxacin, fleroxacin 
and pefloxacin were dissolved in o. 1M NaOH while 
rifampicin and ethionamide were dissolved in O.lM HCI. 
All the solutions were diluted with sterile distilled 
water into different concentrations (Table 8). 
Drug " containing media with of 
pyrazinamide were prepared by mixing the required 
amount of drug solution with the Lowenstein-Jensen 
medium before inspissation . . The medium was dispensed in 
about 7.0 ml amount and was inspissated once at 8S oC for 
50 minutes (Canette et aI, 1969). 
step pH method (Marks, 1964) was used · in 
pyrazinamide susceptibility testing. Three different 
acidic Lowenstein Jensen media (pH 4.75, 4.85, 4.95 
before inspissation) were used for testing each of the -
following drug concentration viz 100, 50, 25 and 0 mg/L. 
This medium contained half the usual amount of malachite 
green and was inspissated once at 85°C for 60 minutes 
instead for 50 minutes as fp~ other drug testing. 
All these media could be · stored at 4°C for a 
maximum of 2 months. 
·c. Minimum Inhibitory Concentration (MIC) Determination 
The - test strains were grown on Lowenstein-Jensen 
medium at 37oC ' for 4 to 6 .weeks. Actively growing cells 
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were scraped off to fill a thick wire loop (3 mm 
,external diameter, 22 SWG) to just full without bUlging. 
These cells were then emulsified in 0.2 ml sterile 
distilled ', water containing a few 2 mm diameter glass 
beads. The r~sulting suspension was shaken mechanically 
for 1 minute at a speed which would just lift the glass 
beads from the bottom of the bottle, and 0.8 ml sterile 
distilled water was added to make a standard 4 mg/ml 
suspension where 0.02 ml of this standard suspension was 
then " inoculated onto ' both the drug-containi"'ng and ,drug-
free Lowenstein-Jensen slopes by a spiral loop (3 mm 
external diameter, 27 SWG). The inoculated slopes were 
' incubated at 35-37oC for 4 weeks except for the rapid-
growers which were incubated for 2 weeks. Slopes of 
M .marinum were incubated at 30oC. The M. I. C. was 
determined as the drug concentr~ti?n where growth of the 
organism was inhibited (i. e. less than 20 colonies on 
the drug containing medium) and at the same time, 
, innumerable colonies w~re found on the drug-free slope. 
In testing pyrazinamide, 0.02 ml of 1 in 10 
dilution of the standard ,4 mg/ml suspension was used for 
inoculation. The incubation period was 6 weeks instead 
of 4 weeks. The lowest ~H that supported a numerous 
growth of mycobacteria on the drug free slope was chosen 
for M.I.C. determination. The criterion for determining 
M.I.C. was the same as the other drugs. 
v. Heavy Metal Tolerance Test 
A. Bacterial strains 
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Mycobacteria isolates, including 8 M.kansasii, 40 
M. gordonae, ' 24 M.scrofulaceum, 34 MAl, 9 M.terrae, 39 
M. fortui tum and 22 M. chelonae are selected among the 
isolates with known plasmid profiles. They were tested 
for cadmium, lead and mercury tolerance. 
B. Reagent and media prep~ration 
1. Heavy metal stock solution preparation 
Cadmium chloride-2.5 hydrate (BDH) , lead acetate-3-
hydrate (Riedel-de-Haen) and mercuric chloride ' (BDH) 
. ' ~ , 
were dissolved in sterile distilled water for preparing 
stock solutions of 1.0 M cadmium ion, 1.0 M lead ion and 
0.1 M mercury ion. 
2. Media preparation 
Middlebrook 7H10 agar (Difco) containing 0.5% (v/v) 
glycerol was used as the basal medium. This basal medium 
was sterilized by autoci~~ing. Ten per cent (v/v) OADe 
(Difco) was added aseptically for enrichment. 
Appropriate amounts of stock solution of the metal salts 
[cadmium chloride (Sigma), lead acetate (BDH) , mercuric 
chloride (Sigma)] were added to give the following 
concentrations : cadmium, ', 10-4M, 10-3M, 10-2M and 10-1Mi 
lead, 10-3 , 10-2M and 10-1Mi mercury, 10-4 , 10-3M and 
, 
10-2M. The media were adjusted to have pH 6.6 (Falkinham 
III et al., 1984) and 10.0 ml from each was dispensed to 
prepare the agar slopes. The media were stored at 40 C 
for a maximum of 2 weeks before used. 
c. Minimum inhibitory concentration (MIC) determination 
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standard suspension of the organism (0. 02 ml, 4 
mg/ml as prepared in the drug susceptibility -test 
procedure) was streaked onto the surface of both the 
metal-containing and metal-free (control) 7HIO agar 
medium. The inoculated slopes w~re then incubated at 35-
37 0 C for 3 weeks. The MIC was determined as the metal 
concentration at which the growth _ of the bacteria was 
inhibited (i.e. le~s than 20 colonies in the metal 
containing medium) together with an innumerable colonies 
found on the -heavy metal free slope. 
VI. Plasmid Analysis of Mycobacteria 
A. Bacterial strains 
Clinical -isolates of mycobacteria, including 200 
M.tuberculosis, 9 M.kansasii, 45 ~ M.gordonae, 24 
M.scrofulaceuim, 5n MAl, 25 M.terrae, 48 M.fortuitum and 
27 M.chelonae, wer~. selected randomly for the study of 
plasmids. Standard strains used were M.tuberculosis 
(H37Rv) " M.bovis (ATCC 35720), M.simiae (ATCC 25275), 
M .kansasii (ATCC 12478) , M .marinum (ATCC 927) ~ 
M.scrofulaceum (ATCC 19981), M.szulgai (ATCC 35799), 
M .gordonae (ATCC 14470) -' M.flavescens (ATCC 14474), 
M.avium (ATCC 13950), M.chelonae (ATCC 14472) and 
M.fortuitum (ATCC 6841). 
B. Extraction procedures 
1.Modified Kado & Liumethod 
The selected organisms were grown in 10.0 ml 
Middleb~ook 7H9 broth (Difco) cont~ining 0.05% Tween 80 
(Sigma) and 10% OADC (Difco). The cultures were 
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incubated at 35-37o C for 3 to 4 weeks. Rapid-growers 
were incubated for 1 week instead. The cultures were 
then treated with O-cycloserine (Oxoid) and ampicillin 
(Oxoid) at -- concentration of 1. 0 mg /ml and 0 . 1 mg /ml 
respectively at 35-37 o C overnight (Crawford et al., 
1981). After harvested by centrifugation at 3000xg, 
cells were re suspended in 1. 0 ml lysing buffer (0. 05M 
Tris buf-fer (Sigma) pH8.0, O.OSM ethylenediamine 
tetraacetic acid (EDTA) (BDH) , 25% sucrose (BOH)) and 
- kept in 4 0 C for 2 - weeks. Cells _were then recovered by 
centrifugation (4000xg, 3 mins, 2SoC) again, -lysed by 
adding 500 ul 3% (w/v) sodium dodecylsulphate (SOS) 
(Sigma) solution in 50 mM Tris (pH 12.4) and 
subsequently - incubated at 56°C for 15 mins (Kado and 
Liu, 1981). The lysates were then mixed with equal 
volume of .p~enol-chloroform-isoamyl alcohol (25:24:1) 
solution, shaken briefly and centrifuged (4000xg, S 
mins, 25 0 C) for separation of phases. The phenol-
chloroform-isoamyl alcohol was removed and 400 ul of 
chloroform was added to remove the residual phenol by 
gentle shaking. After pha~e separation by centrifugation 
(4000xg, 5 mins, 2~oC), 50 ul of the aqueous phase was 
mixed with 10 ul aqueous\ ·, dye solution consisting of 
0.07% (w/v) bromothymol blue (Riedel-de-Haen), 7% SOS 
(w/v) and 33% glycerol (v/v) (Ajax) for electrophoresis. 
Extraction experiment based on this procedure was 
run in ~uplicate for all isolates. 




Nihe plasmid~containing atypical mycobacterial 
isolates and four M.tuberculosis isolates were studied. 
About 5-10 mg mycobacterial cells were suspended into 
0.5 ml saline-EDTA (0.15 M NaCI, 0.1 M EDTA, pH 8.0). 
The bacteria were passed through the French Pressure 
Cell Press · (SLM Instruments Inc. ,USA) at a pressure of 
14000 psi, prior to the SDS· treatment listed above. 
3. Spheroplasts preparation procedure 
The · . procedure . for preparation of sph~roplasts in 
M. aurum was adopted" (Rastogi and Hugo, 1981). The: 
organsims were grown in 7H9 broth (Difco) containing 
0.05% Tween 80 (Sigma) and 10% CADC (Difco) enrichment 
·for 3 weeks until they have reached the exponential 
phase. D-cycloserine (60 ug/ml) , glycine 
(BDH) (1.4%, w /v), EDTA (2 mg/ml), lysozyme (Sigma) (200 
ug/ml), lithium chloride (Merck) ( 1 mg/ml) were added to 
the broth and incubated at 37 0 C for 24 hours with 
agitation. After incubatiori, the cells were harvested by, 
centrifugation (3000xg, 15 mins, 25°C) and resuspended 
in30mM-Tris/HCI buffer (p~ 8.0) with 20% (w/v) ' surcose, 
EDTA (lOmM) and lysozyme (1 mg/ml). The mixture was 
stirred at 37 0 C for 3 hours prior to the cell lysing 
\ 
procedure as listed in the modified Kado & Liu method. 
C. Electrophoresis procedure 
Electrophoresis of DNA containing. lysate was 
carried · out in a vertical lucite slab gel apparatus 
'using 0.7% agarose ( Sigma) ' dissolved in Tris-borate 
· 37 
buffer (89 mM Tris ,base, 2.5 mM disodium EDTA and 8.9 mM 
boric acid (BDH». The gel was run at 35 V (constant 
voltage) for 2 0 hours, stained in a ethidium bromide 
(Sigma) solution (0.4 ug/ml) for 30 min and observed 
over a shortwave UV light source (San Gabriel, USA). 
coaterless instant pack film (Polaroid 667) was used for 
photography. supercoiled DNA Ladder (Bethesda Research 
Laboratory) was used as the molecular size marker. 
D. statistical analysis for correlation study between 
plasmid and drug resistance or heavy metal tolerance 
Simple t-test w~s used to compare the Mrcs of 
different drugs and heavy metals against plasmid 




I. Identification of Mycobacteria 
A. General characteristics of the chromatographic 
profiles 
In general, all the mycobacterial isolates studied 
produced variable amount of saturated and unsaturated . 
fatty acids from 12 to 20 carbon atoms (Table 4, 5, 9, 
10) with major fatty acid of C14:0, C16:1, C16:0, C18:2, 
C18:1, C18:0 · and TBSA (Figure 3-12). The most abundant 
fatty acid found was C16:0, followed by C1~:1. T~gether 
with C18:0 and TBSA, they contributed more than 70% of 
fatty acids in all the mycobacteria species studied. 
The relative amount of different fatty acids 
obtained from GC-MS were different among different 
species (Table 9). Four .peaks (C14:0, C16:1D, C18:0 and 
TBSA) were found to have differentiation value on direct 
observation. The relatively scanty abundance of C14: 0 
made M.tuberculosis, M.kansasii and M.marinum differ 
from other species. C16:1D seemed to be a characteristic 
peak of M.kansasiiand M .. marinum. The relative scanty 
amount of C18: 0 made MAr and M • terrae complex differ 
from the others. Amount of TBSA detected for different 
species showed the most op.vious variation. Mean value of 
\ 
TBSA abundance of M • gordonae and M. scroful aceum were 
0.28% and 1.03% respectively. In fact, most isolates o~ 
M.gordonae (88%) and M.scrofulaceum (64%) · lacked TBSA. 
The relative abundance of TBSA could also be used in the 
differentiation between M.kansasii (6.94%) and M.marinum 
(2.39%), MAr (9.05%) and M. terrae complex J 12.29%) ,as 
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well as M.fortuitum (6.21%) · and M.chelonae (3.75%). 
There were 6 unidentified peaks (Xl to X6) that 
contained less than 1% of the 74 m/ e ion. These . were 
found to have differentiation values among species 
(Figure 5-12). They could be used in the identification 
of M.kansasii (Figure 5,6), M.marinum (Figure 7,8), 
M.fortuitum and M.chelonae (Figure 9-12). Their relative 
amount could be obtained by GLC (Table 10, Figure 
6,8,10) but not GC-MS since the GC~MS were set to list 
only the peaks with ions at m/e· 74. 
B. Discriminant analysis 
-
, 
1. Gas chromatography-mass spectromatry (GC-MS) 
The relative percentage of 22 peaks, from the GC-MS 
were used in the discriminant analysis (Table 9). C20:0 
was excluded in all analysis by the computer because 
this peak failed in the tolerance test during analysis. 
After analysis, standardized canonical discriminant 
function coefficients for each peaks were generated. 
(Table 11,13,15)~ . with these coefficients, all-groups 
scatterplot (X-Y graph) were produced to show the 
clustering of the g~oup members (Figure 13-15) together 
with classification tables (Table 12, 14, 16). 
\ " 
a. Slow growing non-pigmented mycobacteria 
After the determination · of the standardized 
canonical discrimination function coefficients (Table 
11) for ' .the group of slow-growers, clusters of groups 
could be observed in the all-groups scatterplot (Figure 
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13) . The clusters of different groups in this 
differentiation category were too close and could not be 
separated well. This was confirmed by the classification 
table (Table 12) which ·showed that the percentage of 
"grouped" cases correctly classified was 88.04%, 
although it was shown that M.tuberculosis could be well 
predicted (92.3%). 
b. Rapid growing mycobacteria and Mycobacterium 
tuberculosis 
C16:lDwas excluded from the.analysis pf the group 
of rapid-growers because it failed in the tolerance 
test. After the determination of the standardized 
canonical discrimination function coefficients (Table 
·13), three large clusters were plotted on the all-groups 
scatterplot (Figure 14) with 6luster of M.tuberculosis 
separated well from M.fortuitum and M.chelonae. The 
percentage of "grouped" cases correctly classified was 
90.48% (Table 14). 
c. Pigmented mycobacteria 
After the determination of the standardized 
canonical discrimination function coefficients (Table 
15), clusters of groups . could be observed but the 
separation was poor (Figure 15) for the pigmented 
mycobacteria. Cluster of M. scrofulaceum and M. gordonae 
were on ·similar location. From the classification table, 
the percentage of "grouped" cases correctly classified 
was only 81.82% (Table 16). 
2. Gas liquid chr6matography. (GLC) 
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Twenty-eight peaks (22 fatty acid peaks and 6 un-
identified peaks) were used in the discriminant analysis 
(Table 10). As in the analysis of GC-MS, C20:0 was again 
excluded in all analysis because of its failure in the 
tolerance test. 
a. Slow growing non-pigmented mycobacteria 
X3 was excluded in this analysis for its failure in 
the tolerance test. After the determination "of the 
standardized - canonical _discriminatioIJ function 
....  
coefficients (Table 17), all groups were found to 
cluster well in the aI-I-group scatterplot (Figure 16) 
and the boundary of -each species were well defined. In 
-the classification table (Table 18), all members of 
M.tuberculosis and M.marinum were correctly identified. 
Only one member of M.kansasii, MAl and M.terrae complex 
was mis-identified. The percentage of "grouped" cases 
correctly classified was 97.3%. 
b. Rapid growing mycobacteria and Mycobacterium 
, tuberculosis 
Xl, X2, X4, X5, X6 and C16: 1D were excfuded from 
the analysis becau~e of fheir failure in the tolerance 
test. After the determination of standardized canonical 
\ -, 
discriminant function coefficients (Table 19), three 
well defined clusters were found on the all-group~ 
scatterplot (Figure 17). These clusters were ' found to be 
well separated. In the classification table (Table 20), 
. the accuracy and specificity of identification was found 
to be 100%. When diss:riminant analysis was carried on 
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the sUb-species level of M.chelonae, the all group stack 
histogram (Figure 18) and classification table (Table 
21) showed that there were good differentiation between 
M.chelonae ' chelonae and M.chelonae abscussus as only one 
member of M. chelonae chelonae was mis-identified as 
M.chelonae abscussus. The percentage of "grouped" cases 
correctly classified was 96.15%. 
c. Pigmented mycobacteria 
X3 was excluded from , the analysis for_ its .failure 
in the tolerance test. After the determination of the 
standardized canonical discriminant function 
coefficients (Table 22), the all-groups scatterplot 
showed tha t M. kansasii , M .marinum and MAl could be 
clustered out while M.gordonae 'and scrofulaceum shared 
similar position in the plotting (Figure 19). This was 
confirmed from the classification table (Table 23). ' 
Although the overall percentage of "grouped" cases 
correctly classified was bnly 86.36%, this low accuracy 
percentage was merely ,due to the difficulty in 
separating M. scrofulaceum and M.gordonae. 'Only one 
member from M .kan~asii, ' M .marinum and MAl was mis-
identified. Identification , of the rare species including 
L , 
M.simiae, M.szulgai and M.flavescens were 100% correct. 
11. In vitro Drug susceptibility Test 
A~ Mycobacterium tuberculosis 
Mo~t ' M. tuberculosis isolates , including H37Rv were 
found susceptible to all the anti-tuberculous drugs 
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tested (Table 24, 25) with percentage of resistance 
ranging from 0% (cycloserine) to 15.45% (streptomycin). 
Over 90% of M. tuberculosis isolates were resistant to 
pefloxacin, fleroxacin 'and netilmicin while about 55% 
were resistant to gentamicin. Among the aminoglycosides 
(Figure 20), amikacin gave the lowest percentage , 
resistance (1.08%) followed .by kanamycin (1.36%). For 
quinolones, ofloxacin and ciprofloxacin both gave 1.08% 
of resistance (Figure 21). Among other common anti-
tuberculous drug,s, percentage of resistance· were . all 
below 10% except isonIazid (11.38%) (Figure 22). 
About 80% of the isol~tes was found susceptible to 
all the 11 common anti-tuberculous drugs (streptomycin, 
isoniazid, rifampicin, ethambutol, pyrazinamide, 
ethionamide, kanamycin, cycloserine, capreomycin, 
ofloxacin and amikacin) (Table 26). Eleven percent was 
resistant to streptomycin or isoniazid and 2% was 
resistant to both drugs. six per cent (23 isolates) was 
resistant to more than 2 drugs and was termed 'very 
resistant strains'. Nine out of eighteen of these very 
resistant strains were derived from retreatrrient cases 
(Table 27). Upon 9loser 'examination on these 23 'very 
resistant strains' (Tab~e 28), the number of 'very 
\ . 
resistant strains' resistant to ethionamide, amikacin 
and ofloxacin were found to be 3,4 and 4 respectively~ 
Only 2 . isolates were resistant to both . amikacin and 
ofloxacin (Table 29), but they were still susceptible to 
ethionamide and ~ycloserine. 
The. MfC 25 , MIC50 and MIC 90 (drug concentration 
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inhibited 25%, 50% and 90% of isolates respectively) of 
different drugs to M • tuberculosis were determined by 
cumulative percentage plots (Figure 23,24). The MICgO 
for most ~ommon anti-tu~erculous drugs (rifampicin, 
ethambutol, ethionamide, kanamycin, _capreomycin and 
ofloxacin) were below the pre-set break points (Table 
30). Although the MICgO of streptomycin and isoniazid, 
which were members of the first line drugs in the short 
course 'chemotherapy in Hong Kong, were above the pre~set 
-breakpoints, -84.55% and 88.63% of the M :tuberculosis 
isolates gave MIC values below the breakpoints of 
streptomycin and isoniazid respectively (Table 24). 
studies on the cross resistance among the 
aminoglycosides (Table 31) revealed that amikacin · was 
the most effective drug, with only 7 resistant strains 
out of a ; total of 397 isolates including the 28 
additionally selected resistant strains. When an isolate 
was resistant to amikacin, it waS also resistant to the 
otheraminoglycosides tested. Cross resistance on 
quinolone (Table 32) showed that ofloxacin was the most 
effective drug and only ~ isolates were resistant to it. 
When an isolate was resistant to ofloxacin, it was also 
resistant to the other quiholones tested. 
B. Atypical mycobacteria 
1. General characteristics 
When tested against the 11 anti-tuberculous drugs, 
atypical mycobacteria were found to be much more 
resistant than M. tuberculosis (Table 33). All the 
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atypical mycobacteria tested were resistant to isoniazid 
and pyrazinamide while the percentage of resistance of 
M.tuberculosis to these two drugs were only 11.38% and 
1.72% respectively (Tabl~ 24). Among the atypical 
mycobacteria species, M.kansasii was the most sensitive 
species while ' M. chelonae was the most resistant one 
(Table 33). 
2. sensitivity pattern of different species 
a. Mycobacterium kansasii 
All M .kansasii isolates including the reference" 
strains were susceptible to ofloxacin, cycloserine, 
rifampicin and ethionamide (Table 33, 34). MIC90 of 
ethambutol and MIC50 0f fleroxacin and ciprofloxacin 
were below the pre-set breakpriints (Table 35). All 
M.kansasii isolates were resistant to all 
aminoglycosides tested except capreomycin where only 
seven out of 19 isolates were susceptible. When cross 
resistance among quinlones ' was studied, ofloxacin was 
most effective (Table 36) . 
b. Mycobacterium avium-intr~cellulare complex 
Most MAl isolates including the reference strains 
, were resistant to all dru~s' , except cycloserine (Table 
, 37, 38). Quinolones did not show any activity against 
most isolates. MlC 25 of ethambutol, ethionamide and 
,aminoglycosides (except streptomycin, amikacin and 
capreomyqin) 
r 'esistance was 
were below the brea,kpoints. No cross 
found among the aminoglycosides tested 
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(Table 39). 
c. Mycobacterium scrofulaceum 
MIC90 of cycloserine was below the break-point for 
M.scrofulaceum (Table 40). Most isolates including the 
reference strain (Table 41) were resistant to all 
aminoglycosides tested. Among the quinolones, 
ciprofloxacin was more effective than ofloxacin. MIC50 
of ciprofloxacin, rifampicin and ethionamide were below 
their corresponding break-points. 
d. Mycobacterium terrae complex 
MIC90 of all drugs , were above the break points in 
M. terrae complex (Table 42) . . MIC50 of some anti-
·tuberculous drugs (ethambutol, rifampic~n, ethionamide) 
were below the breakpoints. The MIC25 of ofloxacin and 
ciprofloxacin were below the breakpoints while MIC25 of 
aminoglycosides were above. 
e.Mycobacterium fortuitum 
All M. fortui tum isolates including the reference 
strains were resistant to all common anti-tuberculous 
drugs .and aminoglycoside~ except amikacin (Table 43, 
44). About 10% isolates were susceptible to amikacin 
(Table 33). Over 80% of 'isolates were susceptible to 
ciprofloxacin and in . the cross 'resistance study, 
ciprofloxacin was also the most effective drug. Once an 
isolate was resistant to ciprofloxacin, it was also 
resistant to other quinolones (Table 45). MIC 50 bf 
ofloxacin was below the breakpoint. 
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f. Mycobacteriumchelonae 
All M.chelonae isolates were resistant to all the 
drugs tested (Table 46). 
III. Heavy metal toleran~e test . 
Among the three heavy metals tested, mercury showed 
the highest toxicity. It inhibited more than 85% of all 
atypical isolates at 10-3M regardless of species and 
inhibited all isolates at 10- 2M. Lead and cadmium 
inhibited ' all isolates at the concentration of 10-lM . 
Moreover, differeni species responded differently to 
these three metals. M.fortuitum was found to be the most 
resistant species to all these three metal ions (Table 
47, 48, 49). 
IV. Plasmid in Mycobacteria 
A. Mycobacterium tuberculosis 
Two hundred isolates of M.tuberculosis were scanned 
for pla'smids by the modified Kado and Liu procedure 
(Meissner and Falkinham, 1986; Kado and Liu, 1979).' No 
plasmid was detected. Only limited amount qf DNA was 
found on the agarose ge,l after electophoresis (Figure 
25). When compared with the DNA extracts from atypical 
mycobacteria using the same procedure (Figure 25), the 
amount of DNA detected inM.tuberculosis was relatively 
scanty. When the cells were lysed by a French Press to 
ensure a certain degree of cell breakage ·before plasmid 
extract.ion, the amount of DNA detected, especially on 
the position ,of chromosomal band, markedly increased in 
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all species (Figure 26). Such increase was particularly 
obvious in M. tuberculosis. However, although known 
plasmid containing isolates were included, no plasmid 
band could be visualized. 
When the spheroplast ' preparation procedure (Rastogi 
and David, 1981) was used for plasmid extraction, the, 
intensity of DNA bands on the gel markly increased in 
all cases when compared with the results obtained from 
the modified Kado and Liu procedure (Figure 27). When 
this spheroplast procedure was used on 14 M.Euberculosis 
isolates again, plasmid bands appeared in 4 
M.tuberculosis isolates . (Figure 28). 
B. Atypical mycobacteria 
1. General characteristics 
All the atypical mycobacteria species tested were 
. found. to contain plasmid (s) and the percentage of 
isolates containing plasmidsvaries among species (Table 
50) (Figure 29). Members in Runyon's Group 11 were found 
to harboura higher number of plasmids than others. The 
percentage of M.gordonae and M.scrofulaceum isolates 
possessing plasmids were ,about 90% and 80% respectively. 
Moreover, about 60% M. gordonae and M. scrofulaceum 
isolates gave more than orte plasmid band under agarose 
gel electrophoresis (Table 50) (Figure 30). About 40 to ' 
50% of . MAr isolates and M.fortuitum isolates contained 
plasmids but most of them only gave one . plasmid band. 
Only a~out 10% of M .kansasii isolates and M. chelonae 
isol~tes contained detectable plasmids (Table 50). ' 
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The molecular size of the mycobacterial plasmid 
found ranged from 4 KB to 28 KB. In pigmented 
mycobacteria, most plasmids have sizes ranged from 11 KB 
to 17 KB. About 70% of M.gordonae isolates gave a 
plasmid band with molecular size of about 16 KB (Figure 
31). In MAl and M.terrae complex, . the molecular size. of , 
plasmid found distributed evenly from 7 KB to 18 KB and 
11 KB to 18 KB respectively (Figure 32). For the rapid-
growers (M. fortui tum and M • chelonae) , most plasmids 
. found were of 11 KB to '17 KB (F~gure33 L similar to 
those found in the pigmented mycobacteria (Figure 31). 
2. Correlation between drug resistance and plasmid 
No correlation was found between the drug resistance 
of the 16 tested drugs and the presence -of plasmid(s) in 
M.fortuitum, MAl andM.terrae complex on using simple t-
test. P values obtained in all cases were greater than 
0.4 (Table 51,52,53). 
3. Correlation between heavy metal tolerance and plasmid 
No correlation was found between the heavy metal 
(cadmium, lead, mercury) tolerance and the presence of 
plasmid(s) in M.terrae ' complex, MAI, M.gordonae, 
M • scrofulaceum, M • kansasii , M • fortui tum and . M • chelonae 
, 
isolates on using simple t-test. In cadmium tolerance 
test (Table 54), all species gave a p value >0. 4 . In 
lead tolerance test (Table 55), all species gave a p 
value >0.1 and most species even gave a p value >0.4. In 
mercury tolerance test (Table 56), all species except 
M. chelonae gave a p value >0. 05. In M. chelonae, . the p 
50 
value was <0.025. However, the sample size may not be 
enough for this species because plasmid bands were 




I. Identification of Mycobacteria 
. In Hong Kong, the most common species of 
Mycobacteria encountered in the clinical laboratories 
include M.tuberculosis, M.kansasii, M.marinum, M.avium-
intracellulare complex, M. terrae complex, M . gordonae, 
M.scrofulaceum, M.fortuitum and M.chelonae (personal 
communication). These species constituted more than 99% 
of the mycobacteria isolated in Hong Kong. Ususally 4 to 
6 . weeks and 1 to 2 weeks are requir~d for · the 
identification of slow-growers and rapid-growers 
respectively using the conventional biochemical methods. 
Since only a few species are commonly encountered, 
development of a rapid and practical 'differentiation 
scheme ' is invaluable for the clinical laboratories in 
Hong Kong. 
Lipid analysis has proven useful in the 
classification and identification of mycobacteria 
(Welch, 1991). A tree structure identification scheme' 
has been proposed by Tisdall and associates (1979) and 
latter found to be applic,~ble with 95% agreement with 
the conventional biochemical methods (Tisdall et al., 
1982; Mayall, 1985). with ~ ~ high injection temperature, 
some authors used both the -fatty ' acids and the mycolic 
acid cleavage products in the identification (Guerrant, 
Lambert and Moss, 1981). In this study, a lower 
injection temperature was used to prevent the breakage 
of mycolic acids ' and thus all the components used in 
· 52 
this analysis were originated from the relatively low 
molecular weight compounds of the bacteria. Unlike in 
Tisdal·l's experiment where a higher oven temperature 
programme. (max. 300oC) was used for rapid elution of 
high molecular weight fatty acid (C22: 0 C26:0), a 
lower oven temperature programme ' (max. 260) was used in , 
this study. Under this condition ,all fatty acids and 
sapionification products with retention time between 
those ofC12:0 and C20:0 could be well separated in the 
gas chromatograph (Figure 3-12). In contras~t to results 
reported by Luquin e~ al. (1991), some minor peaks such 
as C14:0, C16:1C and · C16:1D were found to possess 
diagnostic value on direct observation (Table 9, 10). 
I 
There were 6 un-identified pea~s that possess 
differentiation values (Table 5, 10). Since less than 1% 
of their ionized products detected by the mass 
spectrometer contained ion of mj e 74 (F igure 5 , 7 , 9) , 
they were probably not fatty acid. As only their 
differentiation values rather than their identities were 
of interest, they were used . wi thout further 
clarification on their molecular structures. 
All common MY90bacterium species were grouped into 
three groups according . to their growth rate and , 
pigmentation (Table 6). Some species appeared in more 
than ·one group because of their variations in 
pigmentation (Sommers and Good, 1986; ·stromerand 
Falkinham, 1989). These included M.kansasii, M.marinum 
. M.avium ·intracellulare complex. Placing these organisms 
into two groups makes . the scheme more appliable in the 
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clinical laboratory. Moreover, since identification of 
M. tuberculosis from the non-pigmented mycobacteria is 
always essential in the clinical laboratory, this ' 
organism . was included in both the slow growing non-
pigmented and the rapid growing mycobacteria for 
discriminant analysis in this study. 
Discriminant analysis is a statistical tool for 
classifying individuals or objects into mutually 
·exclusive groups on the basis of a set of independent 
-va~iables (Armitage, ~ 1977; Dillbn ' and Goldstein~ 1984). 
This technique provides more objective criteria in 
peaks selection and manipulation. Identification scheme 
of the commom mycobacteria species were investigated in 
this study. Analysis of fatty. acids provided by GC-MS 
alone only gave an identification accuracy of 80-90% 
(Table 12, 14, 16). However, when the six un-identified 
peaks were added in the discriminant analysis from the 
GLC profiles, the accuracy of identification was 97.3%, . 
100.0% and 86.4% for the non-pigmented slow-g~owers 
(Table 18) ,rapid-growers (Table 20) and pigmented 
mycobacteria (Table 23) .. respectively. The low accuracy 
in the pigmented mycobacteria was due to the 
difficulties in the diff~rentiation of M.gordonae and 
M.scrofulaceum .. (Figure 19). If the'se two species were 
grouped together, the overall accuracy of classification 
of pigmented ' organisms became over 95% (Table 23). 
Moreover, this limitation probably does not affect the 
usefulness of ' this GLC identification method in the 
54 
clinical laboratory where identification of pathogens is 
most important. In most cases, these 2 organisms are 
less likely to be pathogens and simple urease test and 
Tween hydrolysis test could separate these organisms 
well (Sommers and ,Good, 1986). 
In addition to the ability in differentiation of 
mycobacteria species, this method was even useful in the 
sUb-species differentiation of M. chelonae chelonae and 
M. chelonae abscessus with the accuracy of over 95% 
(Table 21). In using the conventional method, a 5% salt 
tolerance test which ~ required 2-3 weeks has to be used 
to differentiate these two sUb-species (Sommer and 
Goods, 1986). 
since only a few clinical isolates of M. simiae, 
M.szulgai, M.flavescens, M.chitae, M.vaccae and 
M . dierhnoferi could , be included in this study, the 
statistical analysis on these species may not be 
significant. More clinical isolates are required in 
order to establish the identification scheme for these 
species. Nevertheless, these organisms were seldom 
encountered in the clinical laboratory in Hong Kong 
(personal communication) 'and in most cases, they are of 
less clinical significant (Sommer and Goods, 1986). 
" In comparsion with the conventional biochemical 
methods, this procedure of identifying mycobacteria by 
GLC analysis of saponification products , followed by 
discriminant analysis reduces the reporting time from a 
few weeks to only a few hours. No , sophisticated 
technique is involved, and with the help of a personal 
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computer, data analysis is straightforward. The accuracy 
.. is over 95% for most species. Moreover, both the GLC 
quipment and the running cost are inexpensive. In the 
long run, ' '. this procedure is even cheaper than the 
conventional . biochemical methods-. Thus, using GLC and 
discriminant analysis in the identification of 
mycobacteria is technically simple, accurate and 
effective in terms of time and cost. 
II In vitro Drug Susceptibility Test 
A. M.tuberculosis 
Susceptibility test of anti-tuberculous drugs on 
M. tubercuJosis in vitro has always been an important 
aspect of the mycobacteriological service in Hong Kong 
(Hong Kong Tuberculosis Treatment Service (HKTTS) and 
British Medical Research Council Investigation (BMRCI), 
1972; HKTTS and BMRCT, 1974; Hong Kong Chest Service 
(HKCS) and British Medical Research Council (BMRC), 
1991). It has been used in the determination of 
·primary / initial resistance of the · first-line anti-
tuberculous drugs (HKTTS and BMRCI, 1972; HKTTS and 
BMRCI, 1974) , designation of the short course 
chemotherapy (HKCS and BMRC, 1991) and guidance in the 
\ -
choice of chemotherapy given to the patients. At 
present, over 90% of the mycobacterial isolates are 
handled in the Government Mycobacteriology Laboratories 
, in YFSMC where absolute concentration method is used as 
the standard susceptibility testing procedure. 
In this study, eleven available anti-tuberculous 
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drugs including streptomycin, isoniazid, rifampicin, 
ethambutol, ethionamide, pyraziamide, kanamycin, 
capreomycin, cycloserine, ofloxacin and amikacin with ' 
five additional anti-microbial agents including 
ciprofloxacin, pefloxacin, fleroxacin, netilmicin and 
gentamicin were tested for their in vitro activities 
against M.tuberculosis using the absolute concentration 
method. None of these five antimicrobial agents except 
ciprofloxacin was active against M. tuberculosis (Table 
24) . ' However, al~ 'anti-tuberculous drugs gave 
satisfactory results with acceptable ranges of 
percentage resistance (0-16%) (Table 24). The higher 
percentage of resistance to the first-line drugs than 
the reserved second-line drugs are probably due to more 
frequent clinical use of the former. Among the other 
drugs tested including second-line ones ethionamide, 
kanamycin, cycloserine, ofloxacin, ciprofoxacin and 
amikaciri were 'found 1::0 be most effective (Table 24). 
They could be the drugs of choice when the first line 
drugs became ineffective. In particular, kanamycin, 
ofloxacin, ciproxacin anq amikacin were preferred for 
their low toxicities (Fenlon and Cynamon, 1986; Banks, 
1989). Further, ofloxacin knd amikacin were found to be 
the most effective in the cross 'resistance studies 
(Table ,31, 32) . 
The standard anti-tuberculous chemotherapy regimen 
used by, the Government Chest Service in the urban areas 
of Hong Kong is a short course chemotherapeutic regimen 
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consisting of streptomycin, isoniazid, rifampicin and 
pyrazidamide (HKCS and BMCC, 1991). The primary/initial 
'resistance of the clinical isolates to these drugs is 
very impor,tant in the determination of the effectiveness 
of the regimen and the value of pretreatment 
susceptibility tests (Canetti et al, 1969). Studies on , 
the evaluation of the place of pre-treatment 
susceptibility tests in the selection of chemotherapy 
regimen for pulmonary tuberculosis had been conducted in 
Hong 'Kong (HKTTS and BMRCI,1972i HKTTS and ~MRCI, _ 1974) 
which revealed that 'benefit obtained from results of 
accurate susceptibility tests was small despite the fact 
that 30% of patients in the studies had M.tuberculosis 
-isolates resistant to one or more of the 3 standard 
drugs used, namely streptomycin, isoniazid and PAS. The 
results in this study revealed that 80% of the isolates 
were susceptible to all the eleven anti-tuberculous 
drugs, and none of the known pretreatment isolates 
belonged to the group of 'very resistant strains' (Table 
26). Only 13 % of the pretreatment isolates were 
resistant to one or more of the first line drugs 
(streptomycin, isoniazid and rifampicin) currently used 
(Table 26) . Because of 
\ . 
the low primary/initial 
resistance rates to the first line drugs, little would 
be gained by performing routine pretreatment. 
susceptibility test-se Indeed, treatment ' guided by 
inaccurate reports might even lead to lower success than 
,empiric therapy with relatively non-toxic first-line 
drugs. 
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Although the percentages of resistance of 
M. tuberculosis isolates to the anti-tuberculous drugs 
were found to be low, multiply resistant-strains should 
be viewed with vigilance. In the united states, the 
incidence of infection by mul tiple drug resistant 
M.tuberculosis has been increasing with only a curable 
rate of 50% (Fox, 1992). In Hong Kong, the isolation of 
multiply drug-resistant M.tuberculosis has also been 
increasing (personal communication). Some of them were 
.. 
only susceptible to the most toxic ' drugs such . as 
ethionamide and cycloserine as in the 2 multiply 
resistant cases found in this study (Table 29). 
Early detection of these multiply drug-resistant 
strains is obviously important to increase the chance 
of cure. On using the rapid radiometric method, 
susceptibility test results could be obtained within a 
week instead of 3 to 4 weeks using the conventional 
methods - (Roberts et al., 1983). ' As this radiometric 
system is commerically available and has been studied 
extensively (Siddiqu, Libonati and Middlebrqok, 1981; -
Anargros, Astill and Li~, 1990), it may be the best 
available system for the rapid detection of these 
multiple-drug-resistant \strains. Moreover, the high 
running cost on using the radiometric method could be 
offset by reducing the resourc~s devoted to unnecessary 
routine pretreatment susceptibility tests. 
As combined drug regimen · is used clinically, 
comblned drugs - 'instead of single drug susceptibility · 
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tests should be used in the multiply resistant strains 
in a mycobacteriology laboratory. In performing 
susceptibility tests using combined drugs, factors such 
as the drugs interaction, in situ drug concentration, 
drug pharmacokinetics and 6linical responses have to be 
studied before a pragmatic design of these tests can be 
accomplished. 
B. Atypical mycobacteria 
The lack of a standardized method (Young, 1988) and 
. -
the discrepancy betwee.n the in vitro susceptibility test 
results and the clinical outcome (France et al., 1987) 
have made the value of drug susceptibility testing for 
atypical mycobacteria dubious. In this study, absolute 
concentration method was used for easy comparation of 
the test results with the clinical isolates. The result 
re~ealed that atypical mycobacteria were generally more 
resistant than M. tuberculosis to all anti-tuberculous 
drugs tested (Table 33). Different mycobactera species 
-produced different drug susceptibility ' patterns. This 
implicated that accurate identification is impprtant in 
the choice of regimen before commencement of therapy, at 
least for some atypical mycobacteria especially the 
-rapid growers. 
Since all atypcial mycobacteria were found . to be 
resistant to isoniazid and pyrazinamide (Table 33), 
/ 
there is little to gain by performing susceptibility 
tests against pyrazinamide. This .would save 2 weeks 
inCUbation iri drug susceptibility test (Marks, 1964). 
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1. Mycobacterium kansasii 
M.kansasii was the most susceptible organism found 
amongst the atypical mycobacteria species tested (Table 
33). Most - M.kansasii isolates were susceptible to 
ofloxacin, cycloserine, rifampicin, ethionamide and 
ethambutol (Table 35). This is concordant with the 
usefulness of rifampicin and ethambutol in the treatment 
of M .kansasii infection (Ahn et al., '1981). Ofloxacin 
might be clinically useful from results of in vitro 
' studies '(Table 35) and 1 ts relatively low toxici ty 
(Fenlon and Cynamon, 1986). Owing to the high toxicity 
of cycloserine and ethionamide (Hunter et ' al., 1981; 
Bank et al., 1984; Banks, Jenkins and Smith, 1985), 
these drugs should be reserved as the second line 
agents. 
2. Mycobacterium aviizni --intracellulare complex 
The incidence of MAl infection in immunocompromised 
host such as patients with AIDS has been increasing in 
the last decade (Kiehn et al., 1985' ; Young, 1988). MAl 
are highly resistant to the conventional anti-
tuberculous drugs ,(Heifet -- and Lindholm-Levy, 1989) and 
infections caused by these bacteria are difficult to 
, , 
treat. 
MAl isolates were found to be resistant to most 
drugs tested (Table 37) in this study, which )corroborate 
with the findings of others as reported In , literature 
(Heifets and Lindholm-Levy, 1989; Heifets, 1988). 
Ethambutol, ethionamide and aminoglycosides including 
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kanamycin, netilmicin and gentamicin showed slight 
activities (Table 37) and could be considered as members 
in the combined drug chemotherapy. However, due to the 
lack of · .knowledge in the understanding of the 
pathogenesis of diseases caused by MAl and the 
difficulties in extraplotating from the in vitro data to 
the in vivo situation (Young, 1988), the value of 
performing in vitro susceptibility test for this 
organism using isolated drugs remains uncertain. Drug 
combinations with a ·viewt~ delineate synercjism in vitro 
might be more informative (zimmer, DeYoung and Roberts, 
1982; Banks and Jensens, 1987). 
3.Mycobacterium scrofulaceum 
Most M.scrofulaceum isolates were resistant to all 
· aminoglycosides tested (Table 40). This corroborates 
with the stiggestionthat lack of clinical activity of 
aminoglycosides against M .scrofulaceum infections 
(Murray-Leisure, Egan and · Weitekamp, 1987;Umeki, 1989). 
Rifampicin which was the key drugs in the chemotherapy 
of M.scrofulaceum was found to be active in vitro (Table 
40). Ciprofloxac~n and ~ ethionamide possessing of in 
vitro activities (Tabe 40) could also be used in 
combination drug therapy. 
4. Mycobacterium terrae complex 
M • terrae · complex is usually considered · as a 
saprophytic organism (Palmero, Teres and Eiguchi, 1989) 
but diseases caused by this organism had been reported 
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(Karthigusu, Spagnolo and Gow, 1991; Tonner and Hammond, 
1989). Rifampicin and ethambutol had been used in the 
therapy of M. terrae complex infection (Tonner and 
Hamnond, ~989; Rougraff, Reeck and Slama, 1989), though 
clinical improvement on blind treatment was not 
guaranteed. In this study, rifampicin, ethambutol and 
ethionamide were found to be active against most 
M.terrae complex isolates (Table 42) and this might be 
useful in guiding clinical therapy. 
5. Mycobacterium fortui tum ·· 
All M.fortuitum isolates were resistant to all 
drugs tested except amikacin, ofloxacin and 
ciprofloxacin (Table 43). Amikacin and ofloxacin were 
found to be clinically efficaciois in -the tr~atment of 
M.fortuitum infections (Yew et al., 1989). However, the 
hig~ __ .percentage resistance of amikacin (91.3%) was 
unexpected in this study (Table 33) as its in vitro 
activities had been demonstrated by using the disk , 
diffusion method (Wallace, Dalovisio andPankey, 1979). 
This discrepancy demonstrated the limitation iti 
performing in vitro susceptibility test for this 
atypical mycobacteria. Judging from the clinical outcome 
reported in the literatu.,re(Yew et al., 1989), the 
absolute concentration method used -in this study seems -
not appropriate for susceptibility determination of 
amikacin against M .fortuitum, again the use of a 
reliable standardized method with results "correlating 
with' clinical ,outcome should be emphasized. 
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6.Mycobacterium chelonae 
M.chelonae was the most resistant species found in 
this study (Table 33). All isolates were found to be 
resistant" " to all the "drugs tested using the absolute 
concentration method (Table 46) -. However amikacin and 
kanamycin were found to be effective to most M.chelonae " 
tested using disk diffusion method in YFSMC routine 
service (personal commication). Wallace and associates 
(1979) also found amikacin effective both in in vito 
and in vivo situation. This disagreement between 
" " " 
different susceptibility testing method must be excluded 
by developing standard " methods for susceptibility on 
this organism in order that the in vitro susceptibility 
test can be clinically useful. 
Ill. Plasmid analysis in mycobacteria 
Methods including the modified Kado and Liu 
procedure (Meissner and Falkinham, 1986; Crawford and 
Bate, 1986) and salt precipi~ation proce9ure (Hull et 
al., 1984; Crawford and Bates, 1979 ) were tested for 
their suitability for rapid screening of plasmids. The 
former procedure was found to be technically simple and 
the result obtained was reproducible and " thus was 
. \ " .. 
adopted for the screenlng of plasm1d 1n this study. 
A. Mycobacterium tuberculosis 
No plasmid was detected in M.tubercu16;is by using 
the modified Kado and "Liu procedure. Limited amount of 
' DNA found on the agarose gel after gel electrophoresis 
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(Figure 25) indicated insufficient cell breakage on 
using this procedure. This was confirmed by breaking the 
cells with a French Press that resulted in marked 
increase in intensIty of the chromosomal bands. However, 
French Press is not suitable for plasmid isolation 
because of destruction of plasmids due to greater 
shearing force during the procedure. This might 
explained why no plasmid band was detected on using the 
French Press procedure (Figure 26). 
On using the spheroplast procedure, the increase in 
.. 
. ' . ' . . 
intensity of the DNA bands indicated a betterbreakag~ 
of cells (Figure 27). This procedure was probably gentle 
enough to preserve the " plasmid (s) . As " in this study, 
discrete DNA bands in addition to the chromosomal band 
appeared in 4 M. tuberculosis .isolates indicating that 
plasmid may be present in M. tuberculosis (Figure 28). 
However, due to unknown reasons, when ·the working 
solution of lysing buffer [30 mM-TrisjHCl buffer pH 8.0, 
20% sucrose (w/v) , EDTA (10 mM) and . lysozyme (lmg/ml)] 
was run out of stock after a few preliminary studies, 
the fresh batch of lysing buffer could not - lyse the 
cells efficiently. Further studies on the confirmation 
of plasmid by caesium chloride gradient centrifugation 
could not be proceeded. \ 
Up to now, no plasmid " has been isolated from 
M . tuber"culosis . Results in this study indicated that 
plasmids are probably present in M . tuberculosis. The 
failur~'in detection was probably due to the failure in 
sfficient cel"l breakage. Further improvement in this 
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procedure is ' needed to circumvent the cell wall barrier 
of M.tuberculosis to facilitate further molecular 
biology studies. 
B. Atypical mycobacteria 
All atypical Mycobacterium species screened in this 
study were found to contain plasmid(s) (Table 46). 
Plasmids found in M .gordonae, M.terrae complex and 
M .kansasii (Figure 29,30) have never been reported in 
literature. ,Although the percentage of mycobacterial 
isolates containing ~ detectable plasmids varies among 
species (Table 50), this may not be altogether true. 
Any ~tudy concerning plasmid extraction on mycobacteria 
must involve the gentle breakage of cells with the aim 
to preserve the plasmid structure as closed circular 
DNA. The degree of breakage may vary among species or 
evert ' among different isolates within the sam~ species. 
The absence of detectable plasmid may merely be due to 
the insufficient cell lysis rather the actual absence of 
plasmids. Although "plasmid is important in determining 
the antibiotic and heavy metal resistance in most 
bacteria (Moat and Foster, 1988), no relationship was 
found between plasmid profile and drug ' resistance in 
\ , 
this study (p > 0.4) (Table 51-53). This corroborates 
with the findings reported in literature (Masaki et al., 
1989; Wallace et al., 1985). Although plasmid mediated 
, I 
resistance to mercury in M .scrofulaceum had been 
reported (Meissner and Falkinham, 1984), no 
relationship 'was found between the plasmid profile and 
66 
heavy metal (cadmium, lead and mercury) tolerance in 
this study (Table 54-56). - Because of the cell breakage 
difficulties, the lack of correlation does not imply . 
that plasmid is not important in the determination of 
drug or heavy metal resistance in mycobacteria. Much 
work have to be done to tackle the cell breakageproble~ 
before plasmid analysis is useful in the epidemiological 




SUMMARY AND CONCLUSIONS 
Discriminant analy~is on the saponification 
products profile produced by GLC can differentiate most 
commonly ',isolated mycobacteria species with high 
accuracy. As the procedure is 'technically simple and 
cost effective, this GLC identification scheme can be ' 
easily . adopted by the routine mycobacteriology 
laboratory for shortening the identification time from a 
few weeks to a few hours . 
. Although . routine pretreatment drug . . susceptibility 
test of M.tuberculosis are unrewarding, rapid detection 
of multiply resistant strains remains important. 
Development of a rapid, . combined-drugs susceptibility 
test procedure for M .tub'erculosis is urgently needed to 
identify these organisms and allow better prediction of 
treatment outcome. For atypical mycobacteria, different 
species give different susceptibility patterns and this 
might implicate the importance of rapid identification 
before the start of chemotherapy. Based on the results 
of susceptibili ty testing, drugs recommended in 
treating different atypical mycobacterial infections 
were: rifampicin~ ethambutol and ofloxacin for 
M.kansasii; ethambutol, ethionamide and aminoglycosides 
for MAl; rifampicin, ethionamide and ciprofloxacin for 
M . scrofulaceum; rifampicin, ethambutol and ethionamide-
for M. terrae . complex; amikacin and ofloxacin for 
M.fortuitum. However, more investigation is ' needed for 
' better correlation between clinical outcome and in vitro 
68 
susceptibilities of these organisms to various drugs. 
Plasmid profiles of mycobacteria were found to have 
no correlation with drug resistance, nor with heavy 
metal tolerance. Problems in cell lysis make plasmid 
isolation difficult and inefficient. This is especially 
important in M. tuberculosis. Failure in recovering 
plasmid from M.tuberculosis may be a result of poor cell 
breakage rather than the actual absence of plasmids. 
Better cell breakage techniques that would provide a 
gentle but sufficient cell " lysis for obtaining plasmid 
in preserved closed- circular DNA forms have to " be 
developed before plasm~d analysis could be applicable 
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TABLE 1 : Reference strains of mycobacteria: 
Code Species Source 
H37Rv M. tuberculosis NTCC 
ATCC 35720 M.bovis ATCC 
ATCC 12478 M.kansasii ATCC 
TMC 1201 M.kansasii TMC · 
ATCC 927 M.marinum ATCC 
TMC 1218 M.marinum TMC 
ATCC 25275 M.simiae ATCC 
ATCC 14474 M.flavescens ATCC 
ATCC 14470 M.gordonae ATCC · 
ATCC 19981 M.scrofulaceum ATCC . 
ATCC 35799 M.szulgai ATCC 
ATCC 13950 M.avium ATCC 
TMC 724 M.avium TMC 
ATCC 23366 M.aurum ATCC 
ATCCC 14472 M.chelonae ATCC 
ATCC 19627 M.chime ATCC 
ATCC 19340 M. diernhoferi ATCC 
TMC 1323 . M.fortuitum TMC 
ATCC 6841 M. fortuitum ATCC 
ATCC 25795 M.neoaurum ATCC 
ATCC 19420 M.smegmatis ATCC 
Source: TMC: Trudeau Mycobacterial Collection 
ATCC : American Type Culture Collection 


















Table 2 : Mycobacteria for gas chromatography - mass spectrometry analysis 
Species Number of isolates 
'M. tuberculosis 26 
M.kansasii 20 
M.marinum 4 
M. a vium-intracellulare complex 38 
M.terrae complex .4 
M.scrofulaceum 22 
M.gordonae 26 
M. fortuitum 37 





Table 3 : Mycobacteria for gas liquid chromatography analysis 
Species Number of isolates 
M. tuberculosis 31 
M.kansasii 24 
M.marinum 11 
M. a vium-intracellulare complex 24 
M.terrae complex 20 





















Mycobacterial RRT Standard Mycobacterial RRT 
Component Component 
C12:0 15.90 C16:0 - C16:0 23.90 
C13:0 · 18.10 C17B 24.54 
C120H 19.58 C17:1 25.12 
C14:0 20.10 C17:0 C17:0 25.50 
C15B 21.46 C18B 26.22 
C15:0 22.05 C18:2 26.60 
C16B 23.23 C18:1 26.78 
C16:1A 23.39 C18:0 C18:0 27.30 
C16:1 B . 23.47 TBSA TB SA 27.94 
C16:1C 23.55 C19:0 C19:0 - 28.95 
C16:1D 23.75 C20:0 C20:0 
a. The number after 'C' indicates number of carbon. 
b. The number after ';' indicates number of double bonds 
&Ietter followed indicates different structural isomers. 
c. '8' after carbon number indicates a branch 
d. Assignment of a peak name without a corresponding 
standard was fJ1a.de by mass spectroscopy, and thus 
is tentative. 
e. All fatty acids were methyl esters. 
30.70 
f. RRT: Relative retention time in minutes (relative to C16:0) 
\ 
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Mycobacterial RRT Standard Mycobacterial 
Component Component 
C12:0 18.51 C16:1C 
X1 19.32 C16:1 D 
C13:0 20.32 C16:0 C16:0 
X2 22.04 C17B 
C120H 22.24 X6 
X3 22.61 C17:1 
C14:0 22.77 C17:0 C17:0 
X4 23.46 C18B 
X5 24.02 C18:2 
C15B 24.40 C18:1 . 
C15:0 24.74 C18:0 C18:0 - . . 
C16B 26.00 TBSA TBSA 
C16:1A 26.17 C19:0 C19:0 
C16:1 B 26.23 C20:0 C20:0 
a. The number after 'c' indicates number of carbon. 
b. The number after ':' indicates number of double bonds 
&Ietter followed indicates different structural isomers. 
c. '8' after carbon number indicates a branch 
d. Assignment of a peak name without a corresponding 
standard was made by profile produced by GC-MS 
















f. RRT: Relative retention time in minutes (relative to C16:0) 




TABLE 6 : Grouping of mycobacteria for discriminant analysis 
Group 1 . 
Pigment Producers: yellow or orange pigment observed macroscopically 






7 . M.simiae 
8 M.szulgai 
Group 2 








5 M. tuberculosis 
6 M. terrae complex 
Group 3 
Rapid growers : Growth within 5 days · 
1 M.chelonei 
2 M.chitae 
3 M. diernhoferi 






TABLE 7 : Mycobacteria for drug susceptibility test 
M.tuberculosis : 369 ( Dec.,1988 from YFSMC) 
, 28 (selected resistant isolates) 
Atypical 
mycobacteria 










· M.avium complex: 
Atypical mycobacteria: 
(randomly selected) 
standard strains . . 
6 'M. terrae 
· 28 
· 2 M.fortuitum 
· 
23 
· 3 M.chelonae 
· 11 
· 1 M.vaccae · 1 























































Table 8 : Drugs used in the susceptibility tests 
BREAK 
TEST POINT 
DRUG SOURCE CONCENTRATIONS (mg/L) (mg/L) 
a Streptomyc~ (SM) , Specia 8,16,32,64 8 * 
Isoniazid (INH) Sigma 0.2,1 0.2, * , 
Rifampicin (RIF) Sigma 16,32,64 32 * 
b Ethambutol (EMB) Sigma 1.4, 2.0, 2.8, 4.0, 5.6, 8.0 2.8 * 
Pyrazinamide (PZA) Sigma 25,50,100 50 * 
Ethionamide (ETH) Sigma 10,20,40,56,80,112,160 56 * 
a Kanamycin (KM) Sigma 4,8,16,32,64 16 * 
a Capreomycin (CAP) Sigma 32,64,128,160,256 32 * 
D-cycloserine (CS) Sigma 10,20,28,40,56 28 * 
Ofloxacin (OF) Daiichi 0.6, 1.2, 2.4, 4.8 2.4 * 
Ciprofoxacin (CIP) Bayer 0.6, 1.2, 2.4, 4.8 2.4 # 
Fleroxacin (FO) M&B 0.6, 1.2, 2.4, 4.8 .,. 2.4 # , 
Pefloxacin (PEF) M&B 0.6, 1.2, 2.4, 4.8 2.4 # 
a Amikacin (AK) Bristol 4,8,16,32,64 8 * 
Netilmicin (NET) Schering ' 4,8,16,32,64 16 # 
Gentamicin (GM) David Bull 4,8,16,32,64 16 # 
Lab. 
Note: 
a. in form of sulphate salt 
b. in form of hydrochloride 
* Breakpoints were recommended by D.A.Mitchison (personal communication) 



























TB KAN MAR MAl TER SCR GOR 
0.28 0.36 0.20 0.1 1 0.27 0.59 0.68 
0.01 0.13 0.04 0.05 0.06 0.05 0.13 
0.08 0.13 0.04 0.02 0.13 0.21 0.18 
1~1~j~j~j~j~1j~~~~~jt~j~j~jjj~j~j~j~j~~g1j~jt~~I11~1j~~jlt~j 5.35 5.34 5.96 6.23 
0.02 0.19 0.08 0.15 0.01 0.09 0.05 
0.56 0.39 0.48 0.73 0.59 0.43 0.32 
0.21 0.32 0.14 0.10 0.02 0.18 0.51 
0.78 0.77 1 .62 0.29 2.97 0.78 0.72 
1 .88 1 .40 2.93 1 .91 1 .57. 2.70 3.08 
1 .08 1 .12 0.83 5.50 3.10 4.43 4.15 
NO lj~~ljljlj~jllJjR~~~l~j~l~l~ljlalj~IJll~lI 0.25 NO T T 
28.35 37.20 33.35 39.01 39.35 35.34 32.81 
0.46 0.41 0.68 0.96 0.40 0.17 0.13 
0.51 0.22 0.57 0.39 0.24 0~34 0.40 
2.78 0.88 1 .55 0.65 0.94 0.63 0.51 
0.46 0.02 0.23 0.14 0.01 0.04 0.02 
8.41 7.74 7.98 3.55 3.10 9.08 9.97 
23.81 24.45 27.57 22.12 21 .33 23.91 25.84 
16.14 13.29 15.7,1 t~~~~~~~s.~$il~l~jt~I~j~a~b.$jjf 12.88 13.11 
:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.: ljj~l~1~1~jg~§~jj~lf':':':':'9':=O=5:':':'llI1!11Ig~gil11111~j~ljljljl11UI*~jjl~j~1~1~jtR1:g§~1~1~1 llIl9ilgtl~ 6.94 
0.61 0.04 0.07 0.02 NO 0.08 0.06 





















6.21 flt~l3tis.lI~ ;.:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.;.:.:.: 
0.20 0.03 
0.38 0.17 
Note: a. The number after 'C' indicates number of carbon 
Key: 
b. The number after ':' indicates number of double bonds 
&Ietter followed indicates different structure isomers. 
c. 'B' after carbon number indicates a branch 
d. All values in the table are the mean values 
e. Peaks that possess differentiation value on direct observation 
were shaded 
TB : Mycobacterium tuberculosis 
KAN .' Mycobacteria kansasii 
MAR : Mycobacteria marinum 
MAl : Mycobacteria avium-intracellulare complex 
TEA .~ Mycobacteria terrae complex 
SCR .' Mycobacteria scrofulaceum 
GOR : Mycobacteria gordonae 
FORT .' Mycobacteria fortuitum 
CHEL " Mycobacteria chelonae 
TBSA : Tuberculostearic acid 
NO : Not Detected \ - , . 










TB KAN MAR MAl 
0.31 0.39 0.36 0.21 
NO :~:1:1:1:!:9*§~1:1:11 NO NO 
0.15 0.17 0.18 0.10 
0.16 0.57 0.28 
.................... 
IIHMb.lff :.:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.: 
0.12 0.10 0.13 0.05 
NO NO NO NO 
:~1~1~1~1d:~~*~~1~:~:j1jllll:lli~!g:l1l1l1jlj1j1l1l1l1l~tlj:lljl 6.34 
NO 0.25 0.39 NO 
ND ~1111l11111~§1~111~111 0.14 ND 
0.14 0.28 0.24 0.37 
0.70 0.43 0.14 0.65 
0.24 0.58 0.44 0.06 
0.38 0.32 0.05 0.49 
1 .88 2.18 3.49 0.81 
1 .03 0.02 NO 7.93 
NO :ljl1l1l:l:~~§§l1l~l~l:ljl:l1l:l1:~:11:11:l:1:l1 NO 
29.83 34.42 29.95 33.91 
0.55 0.21 0.36 0.37 
T 0.01 ~1~1j1~jj1~jjj~~~jl*11~jljj 0.01 
1 .04 0.21 0.24 0.53 
2.76 1.06 0.64 0.50 
0.19 0.10 0.06 0.02 

























SCR GOR FORT CHEL 
0.56 0.75 0.23 0.24 
0.01 0.02 NO NO 
0.08 0.14 0.2 0.17 
0.33 0.39 NO NO 
0.24 0.25 0.08 0.28 
NO NO ::~:1:111:1Q:~g!:l::11 0.01 
4.2 4.23 6.43 5.96 
~l~lt~~~g~~g§l~~~~~~t~~~lj~ljlt~l~~l~l~lj NO NO 
T 0.02 ND NO 
0.15 0.28 0.51 0.20 
2.88 0.15 0.48 0.33 
0.24 0.68 0.21 0.10 
0.77 1 .05 0.23 0.49 
2.31 1 .43 0.37 2.33 
1.76 2.44 8.45 1 .28 
NO 0.01 NO NO 




0.1 1 0.04 NO ND 
0.35 0.32 0.70 0.46 
0.37 0.32 0.51 0.50 
0.07 0.10 0.01 NO 




















23.91 21.11 26.97 23.18 18.01 25.05 24.67 23.77 31.06 
;:::li§~m;:! 1 ~: ~~~::i;;j;~:;:r!:iI!~!:11~i~IIIIII::::i::§j:;~;i;;:i:iti~,:;:: :: ~~ ii:i~~ii:i 
0.43 0.15 0.02 NO 0.05 0.28 0.24 0.19 0.01 
C20:0 1.87 0.52 0.72 1.01 0.86 2.00 1.47 0.48 0.13 
Note: a. The number after 'e' indicates number of carbon 
b. The number after':' indicates number of double bonds 
&Ietter followed indicates different structure isomers. 
c. 'B' after carbon number indicates a branch 
d. All values in the table are the mean values 
e. X1 to X6 were un~identified peaks 
f. Peaks that possess differentiation value on direct observation 
were shaded 
Key : TB : Mycobacterium tuberculosis 
KAN : Mycoqacteria kansasii 
MAR : Mycobacteria marinum 
MAl : Mycobacteria avium-intracellulare complex 
TER : Mycobacteria terrJe complex 
SCR : Mycobacteria scrofulaceum 
GOR : Mycobacteria gordonae 
FORT : Mycobacteria fortuitum 
CHEL : Mycobacteria chelonae 
TBSA : Tuberculostearic acid 
NO : Not Detected 


























standardized canonical discriminant function coefficients 
of slow growing non-pigmented mycobacteria based on 




























































































Table 12 Classification table of slow growing non-pigmented 
mycobacteria based on GC-MS analysis of fatty acid 
\ 
Classification Results -
Actual No. of Predicted Group Membership 
-Group Cases 1 2 · 3 4 5 
--------
------ ------- ------- ------- ------- -------
Group 1 26 24 " 0 2 0 0 
92.3% O~ • 0 7.7% O~ 
• 0 .0% 
Group 2 20 2 17 0 1 0 
10.0% 85.0% .0% 5.0% .0% 
Group 3 4 0 1 3 0 0 
O~ 
• 0 
25.0% 75.0% O~ 
• 0 .0% 
Group 4 38 0 3 1 34 0 
O~ 
• 0 
7.9% 2.6% 89.5% O~ • 0 
Group 5 4 0 1 0 0 3 
O~ 
• 0 
25.0% O~ • 0 O~ 
• 0 75.0% 





4 M.avium-intracellulare complex 




Table 13 Standardized canonical discriminant function 
coefficients of the rapid growing mycobacteria 




FUNC 1 FUNC · 2 
C12:0 -.03504 .30086 
C13:0 .42408 .14753 
C120H .16751 .19433 
C14:0 1.15606 1.86462 
C15B .05202 .50499 
C15:0 .29154 .79235 
C16B -.18895 .06609 
C16:1A .36456 .56827 
C16:1B .75470 .71447 
C16:1C 1.31918 .37226 
C16:0 3.74255 5.48167 
C17B -.00341 .22283 
C17:1 .43202 .51535 
C17:0 -.48223 . .. --1.09583 
C18B .01033 . .20480 
C18:2 1.23266 2.21267 
- C18: 1 2.26299 4.33608 
C18:0 1.41714 2.15623 
TBSA .59137 .89150 
C19:0 .52864 -.12225 




Table 14 Classification table of rapidly growing mycobacteria 















































. C12: 0 




















standardized canonical discriminant function 
coefficients of pigmented mycobacteria based 




























































































Table 16 Classification table of pigmented mycobacteria based 
on GC-MS analysis of fatty acid 
\ 
Classification Results -
. Actual ·No. of Predicted Group Membership . 
Group Cases 1 . 2 3 4 
.-
5 
--------. ------ ------- ------- ------- ------- . -------
Group 1 20 18 0 0 0 2 ., '. 
90.0% .0% .0% O~ • 0 10.0% 
Group 2 4 0 2 1 1 0 
.0% 50.0% 25.0% 25.0% O~ • 0 
Group 3 22 0 2 14 5 1 
.0% 9.1% 63.6% 22.7% 4.5% 
Group 4 26 0 0 5 21 0 
O~ 
• 0 O~ • 0 19.2% 80.8% .0% 
Group 5 38 2 0 0 1 35 
5.3% .0% O~ • 0 2.6% 92.1% 






5 M.avium-intracellulare complex 
\ 
10). 
Table 17 : Standardized canonical discriminant function 
coefficients of the slowing growing non-pigm~nted 







































































































































































Table 18 Classification table of slow growing non-pigment 






. Actual No. of Predicted Group Membership , 
. Group Cases 1 2 3 .~ 5 
--------
------ ------- ------- ------- ------- -------
Group 1~' 31 31 0 0 0 0 




Group 2 24 1 23 0 0 0 
4.2% 95.8% .0% O~ 
• 0 .0% 
Group 3 11 0 0 11 0 0 
O~ 




Group 4 24 0 0 0 23 0 
.0% .0% o~ • 0 95.8% O~ 
• 0 
Group 5 20 ._ .. 0 0 0 1 19 
O~ 
• 0 .0% O~ • 0 5.0% 95.0% 
Group 6 1 0 0 0 0 0 









4 M.aviurn-intracellulare complex 








































standardized canonical discriminant function 
coefficients of the rapid growing mycobacteria 
based on GLC -analysis of saponification products 
FUNC 1 FUNC 2 FUNC 3 FUlj~ 4 FUNC 
.-58696 -.13085 _ 1.04740 1.81388 - .40135 
.61831 .12590 -.21697 -.80395 -.24422-
-.66226 1.53735 .86693 -1.50588 -1.72869 
":.36245 -.18942 .27328 .46906 -.17565 
-.37521 .78551 1.77747 - 2.26012 .27710 
.01670 -.16570 .37995 .13146 -.31203 
-2.56484 5.20780 4.06243 6.94962 -2.68332 
1.40840 -6.45013 3.58102 2.72883 6.59369 
2.16088 1.30588 -1.21886 .04603 -1.13011 
.79603 .29660 .55760 .74775 -.59091 
-.13557 -.36855 1.01874 1.24285 -.11785 
.20536 .99220 4.59568 4.18011 .54166 
-.25517 .25069 .76834 .67530 .34362 
-.51211 .22501 .37154 .14455 .16982 
1.96067 -.48064 1.29687 1.19643 -.06704 
-.01331 .15349 -.24678 -.20652 .02311 
.20874 .42896 2.03492 2.86381 .71224 
.57533 1.17093 4.79967 5.11594 .49866 
.09147 .92559 2.80265 4.84949 .26515 
.73669 .24049 2.91347 3.08547 .01783 
-.16763 .14493 .45025 .54783 .25545 




Table 20 Classification table of rapidly growing mycobacteria 
and M.tuberculosis based on GLC analysis of 
saponif~cation products 
Classification Results · ~ . 
Actual No. of Predicted Group Membership 
Group Cases 1 
-------- ------ -------
Group 1 31 31 
100.0% 
Group 2 20 0 
.0% 
Group 3 26 0 
O~ • 0 
Group 4 1 0 
.0% 
Group 5 1 0 
.0% 
Group 6 1 0 
.0% 

































3 4 5 
------- ------- -------
0 0 0 
.0% .0% .0% 
0 0 0 
.0% O~ • 0 .0% 
26 0 0 
100.0% O~ • 0 O~ • 0 
0 1 0 
.0% 100.0% O~ • 0 
0 0 1 
.0% .0% 100.0% 
0 0 0 
















Table 21 Classification table of M.chelonae based on GLC 
an~lysis of saponification product 
Classification Results _. 
Actual Group 

















Percent of "grouped" cases correctly classified: 96.15% 
Symbols used in Plots 
Group Species 
1 M.chelonae chelonae 
2 M.chelonae abscussus 
\ 
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Table 22 Standardized Canonical Discriminant Function Coefficients 
of pigmented mycobacteria based on GLC analysis of 
saponification products 
FUNC 1 FUNC 2 FUNC . 3 FUNC 4 FUNC ·5 "':' . FUNC 6 
C12 0 .36257 .33536 ~-.40379 .28354 .59.744 ·· .. · ~-.46996 
Xl .13655 .05569 -.13804 .24469 · -.09560· .12134 
C13 0 .06774 -.01447 .11254 .29730 -.08874 .06869 
X2 -.36692 -.06233 -.16822 .54022 .34005 -.23711 
· C120H .35059 -.03522 .05430 .20515 -.25447 -.18148 
C14 0 .57812 .19798 .69736 1.34601 -.02341 1.34921 
-X4 -.17830 .34887 -.87295 .21082 .31019 1.11713 
X5 -1.27880 .18878 .43689 .26815 .33636 .41797 
C15B2 -.09327 .07999 -.11716 .57497 -.12068 .07793 
C15 0 .94400 .12898 .·45326 .88355 1.46229 1.75597 
C16B2 -.20830 .09780 -.09864 .24511 .17632 -.00194 
C16 lA -.06330 -.03235 -.11405 .40119 .15583 .77672 
-C16 1B .21267 .13289 .38470 .21069 .91106 .61173 
-C16 1C .62829 .37716 .53087 1.04943 1.04726 .88361 
-C16 10 -.27827 .28991 .34277 .54798 .03662 .93087 
-C16 0 .88715 .96875 .44493 2.10684 .79222 1.95445 
·C17B .19635 .38727 · .24241 .68039 .30750 .40427 
X6 .26589 .42378 .29001 .23076 -.17275 .02986 
C17 lA .21490 .05103 -.12425 -.04380 .21481 .14305 
-C17 0 -.67523 .26228 .36378 .12010 -.22095 .47856 
C18B -.04519 .03623 -.09022 .55758 -.30838 .03872 
C18 2 .59482 .93605 .60494 1.14997 1.23483 1.20916 
-C18 1 1.06952 1.06738 -.14240 1.65546 .57435 1.95858 
C18-0 .84997 · 1.01299 -.07367 1.92355 1~73829 2.09463 
TBSA 1.48746 .41039 .42351 .93627 1.45265 .80069 




































































































































































































































































































































































































































































































































Table 24. Percentage resistance of M.tuberculosis against the 16 'drugs tested 
DRUG Sensitive Resistant 0/0 Resistant 
-----------------------------------------------------------------
Streptomycin 312 57 15.45 
Isoniazid 327 42 11.38 
Rifampicin 346 23 6.23 
Ethambutol 352 17 4.61 
Pyrazinamide 343 6 1.72 
Ethionamide 365 4 - 1.08 
Kanamycin 364 " 5 ' 1.36 
! Capreomycin ' 342 27 7.32 : , 
Cycloserine 369 0 0.00 
Ofloxacin 365 4 1.08 
Ciprofloxacin 365 4 1.08 
Pefloxacin 5 364 98.64 
Fleroxacin 32 337 91.33 
Netilmicin 12 357 96.75 
Amikacin 365 4 1.08 
Gentamicin 162 207 56.10 
\ 
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Table 25 : Sensitivity pattern of M.tuberculosis H37Rv 
'Drug MIC (mg/L) Interpretation 
-----------------------------------------------
Streptomycin 8 Sensitive 
Isoniazid 0.2 -Sensitive 
Rifampicin 16 Sensitive 
Ethambutol 1.4 Sensitive 
Pyrazinamide 25 Sensitive 
Ethionamide 40 Sensitive 
Kanamycin 16 - Sensitive 
Capreomycin 32 Sensitive 
Cycloserine 10 Sensitive 
Ofloxacin 1.2 Sensitive 
Ciprofloxacin 1.2 Sensitive ' -
Pefloxacin 4.8 Resistant 
Fleroxacin 2.4 Sensitive 
Netilmicin >64 Resistant 
Amikacin 8 Sensitive 
Gentamicin 32 Resistant 
\ 
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Table 26 : Susceptibility profile of clinical isolates of M.tuberculosis 
against 11 anti-tuberculous drugs 
Cumulative 
S.T. profile " Number . Percentage Percentage 
All:S 297 80.5 80.5 
SM : R 28 7.6 88.1 
INH: R 12 3.3 91.4 
SM+INH: R 7 1.9 93.3 
INH+RIF : R 1 0.3 93.6 
SM+RIF: R 1 0.3 93.9 
SM+INH+RIF : R 4 1 94.9 
INH+RIF+EMB :.R 1 0.3' 
-
95.2 
" R > 3 DRUGS · 18 · 4.8 100 
Note: 
1.11 drugs: SM, INH, RIF, EMB, PZA, ETH, KM, CAP, CS, OF, AMI 
2. S : Sensitive 
3. R : Resistant 
4. All : all 11 drugs 
5. Strains were sensitive to the remaining drugs not shown in the table 
\ 
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Table 27. Patient categories of the 'very resistant strains' of M.tuberculosis 
18 'very resistant strains' 
Pretreatment :0 





Table 28 : Susceptibility of the 18 'very resistant strains' 
of M.tuberculosis against KM, OF, ETH, AK 
Resistant-to KM : 5 
Resistant to OF : 4 
Resistant to AK : 4 
Resistant to AK+OF : 2 
Resistant to ETH : 3 
, / 
Table 29 : Susceptibility profiles of the 2 'very resistant strains' 
of M.tuberculosis that were resistant to both AK & OF 












Ami kac in 
S : Sensitive 















Table 30. MIC 25,MIC 50 and MIC 90 of the 16 drugs tested against M.tuberculosis 
DRUG 



































MIC : Minimum Inhibitory Concentration (mg/L) 
\ -
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Figure indicates n.umber of resistant isolates 

















OF CIP PLEFO 
Figure indicates number of resistant isolates 




Table 33 : Percentage of resistance of 16 drugs against 

























M.TB M.KAN M.AVI 
'. 15.5 . 100.0 100.0 
1.4 100.0 53.6 
7.3 63.2 78.6 
96.8 100.0 53.6 
1.1 94.7 82.1 
56.1 100.0 53.6 
1.1 0.0 78.6 
1.1 15.8 78.6 
98.6 89.5 100.0 
91.3 31.6 89.3 
0.0 0.0 7.1 
4.6 5.3 71.4 
6.2 0.0 96.4 
. 11.4 100.0 100.0 
1.1 0.0 53.6 




































































Table 34 : Sensitivity pattern of M.kansasii TMC 1201 & ATCC 12478 
TMC 1201 ' ATCC 12478 
Drug MIC (mg/L) Interpretation MIC (mg/L) Interpretation 
Streptomycin 16 Resistant 16 Resistant 
Isoniazid >1 Resistant >1 Resistant 
Rifampicin 16 Sensitive 32 Sensitive 
Ethambutol 1.4 Sensitive 1.4 Sensitive 
Pyrazinamide >100 Resistant >100 Resistant 
Ethionamide 20 Sensitive 56 Sensitive 
Kanamycin >64 Resistant 64 Resistant 
Capreomycin ' 32 Sensitive , 32 Sensitive 
Cycloserine 10 . Sensitive 10 Sensitive 
Ofloxacin . 0.6 Sensitive 0.6 Sensitive 
Ciprofloxacin 0.6 Sensitive 0.6 Sensitive 
Pefloxacin 4.8 Resistant 4.8 Resistant 
Fleroxacin 1.2 Sensitive 1.2 Sensitive 
Netilmicin >64 Resistant 64 Resistant 
Amikacin 16 Resistant 8 Sensitive 
Gentamicin 32 Resistant 32 Resistant 
\ 
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MIC 25 , MIC 50 
18 23 







































a. Figure indicates number of resistant isolates 
























MIC 25 MIC 50 MIC 90 
25 34 
Ulgl1l~l~l1l~l1ljl1l1J1l~l~l~l1J1l~l~l~l~l1l~ 21 
. 45 100 
[l§lt1111lt11l11jl1l1l1111jlj11ljl111ljjjljljljl111 2o 
11 28 














































Table 38 : Sensitivity pattern of M.avium TMC 724 & ATCC 13950 
TMC 724 ATCC 13950 
Drug .MIC (mg/L) Interpretation MIC (mg/L) Interpretation 
Streptomycin >64 Resistant 64 Resistant 
Isoniazid >1 Resistant >1 Resistant 
Rifampicin >64 Resistant >64 Resistant 
Ethambutol >8 Resistant >8 Resistant 
Pyrazinamide >100 Resistant >100 Resistant 
Ethionamide · · 112 Resistant 112 Resistant 
Kanamycin . >64 Resistant >64 Resistant 
-
.. Capreomycin >256 Resistant- . >256 Resistant 
Cycloserine 10 Sensitive · 28 Sensitive 
Ofloxacin >4.8 Resistant >4.8 Resistant 
Ciprofloxacin >4.8 Resistant >4.8 Resistant 
Pefloxacin >4.8 Resistant >4.8 Resistant 
Fleroxacin >4.8 Resistant >4.8 Resistant 
Netilmicin >64 Resistant >64 Resistant 
Amikacin · >64 Resistant >64 Resistant · 













SM ·. KM CAP NET 
a. Figure indicates number of resistant isolates. 






















































>1 >1 >1 
!1§.gl~l~1~l~1~1~l~1~~ll~1~~~lll~l~l~11l11~~~~~l§§1~l~1~l~l~lll~j~lllll~ljl~l~lll~l~l~lll~lj 1 60 


















: Minimum Inhibitory Concentration (mg/L) 
\ 
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Table 41 : Sensitivity pattern of M.scrofulaceum ATCC 19981 
Drug MIC (mg/L) Interpretation 
Streptomycin 64 Resistant 
Isoniazid >1 Resistant 
Rifampicin 64 Resistant 
Ethambutol >8 Resistant 
Pyrazinamide >100 Resistant 
Ethionamide 80 Resistant 
Kanamycin. 64 Resistant 
Capreomycin 160 Resistant 
Cycloserine 20 Sensitive 
Ofloxacin 4.8 Resistant 
Ciprofloxacin 2.4 . Sensitive -
Pefloxacin ·>4.8 Resistant 
Fleroxacin . >4.8 Resistant 
Netilmicin >64 Resistant 
Amikacin >64 Resistant 
Gentamicin >64 Resistant 
\ 
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>1 >1 >1 
ilgqlj~j~lll~jljllllljlll1l1l1l1l1l1l1~llllllll§gllll~1l111l111l1l1l1l1l1ljlIjljljlIj > 1 60 


















: Minimum Inhibitory Concentration (mg/L) 
\ 
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MIC 25 MIC 50 MIC 90 
. >64 >64 >64 
>64 >64 >64 · 
60 100 >256 
>64 >64 >64 
. l~j~jj~1j1jI~j~j~j~Ij~j~j~j~lI~1~1~Il~j 20 >64 
52 >64 >64 
>4.8 
4.6 
4.4 >4.8 >4.8 
2.7 >4.8 >4.8 
>56 >56 >56 
8 >8 >8 
>64 >64 . >64 
>1 >1 >1 
160 >160 >160 
>100 >100 >100 


















Table 44 : Sensitivity pattern of M.fortuitum TMC 1323 & ATCC 6841 
TMC 1323 ATCC 6841 
Drug MIC (mg/L) Interpretation MIC (mg/L) Interpretation 
Streptomycin >64 Resistant >64 Resistant 
Isoniazid >1 Resistant >1 Resistant 
Rifampicin >64 Resistant >64 Resistant 
Ethambutol >8 Resistant >8 Resistant 
Pyrazinamide >100 Resistant >100 Resistant 
Ethionamide 160 Resistant ·112 Resistant 
Kanamycin >64· Resistant >64 . Resistant 
Capreomycin 64 Resistant · >256 Resistant 
Cycloserine >56 Resistant . >56 Resistant 
Ofloxacin 0.6 Sensitive. 1.2 Sensitive 
Ciprofloxacin 0.6 Sensitive 0.6 Sensitive 
Pefloxacin 4.8 Resistant :>4.8 Resistant 
Fleroxacin ·4.8 Resistant 4.8 Resistant 
Netilmicin >64 Resistant >64 Resistant 
Amikacin 8 Sensitive 16 Resistant 
Gentamicin 32 Resistant 64 Resistant 
\ 
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a. Figure indicates number of resistant isolates 






Table 46: MIC 25,MIC 50 and MIC 90 of the 16 drugs tested against M.chelonae 
DRUG MIC 25 MIC 50 . MIC 90 Breakpoint 
-------------- --------- --------- --------- ------ -----------
Streptomycin >64 >64 >64 8 
Kanamycin >64 >64 >64 16 
Capreomycin >256 >256 >256 32 
Netilmicin >64 >64 >64 16 
Amikacin >64 - >64 >64 8 
Gentamicin >64 >64 >64 16 
Ofloxacin >4.8 >4.8 >4.8 2.4 
Ciprofloxacin ->4.8 _>4.8 >4.8 2.4 '!'" 
Pefloxacin >4.8 >4.8 >4.8 2.4 
Fleroxacin >4.8 >4.8 >4.8 2.4 
Cycloserine >56 >56 >56 28 
Ethambutol >8 >8 >8 2.8 
Rifampicin - >64 >64 >64 32 
Isoniazid >1 >1 >1 0.2 
Ethionamide 110 150 - >160 56 
Pyrazinamide >100 >100 >100 50 
MIC : Minimum Inhibitory Concentration (mg/L) 
\ -
133 . 
Table 47. Susceptibility of different mycobacteria species against Cadmium 
a M.I.C. (molar) 
Species -4 -3 -2 -1 MEAN 
MAl b 14.70 58.80 20.60 5.90 -2.82 
M.terrae complex 0.00 11.10 66.70 22.20 -1.89 
M.kansasii 12.50 37.50 50.00 0.00 .... 2.63 
M.scrofulaceum . 0.00 45.80 54.20 · 0.00 -2.46 
. M.gordonae 25.00 ' 30.00 37.50 7.50 · -2.73 
M~ fortuitum '0.00 '12.80 2.60 84.60 -1.28 .' 
M.chelonei 22.70 31.80 22.70 22.70 -2.54 : 
Note: 
a. M.I.C. expressed in logarithmic v.alue of 10 
b. Figure in percentage 
\ 
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Table 48. Susceptibility of different mycobacteria species against Lead 
a M.I.C. (molar) 
Species ,-3 -2 
MAl b 0.00 70.60 
M.terrae complex ' 0.00 55.60 
M.kansasii 0.00 87.50 
M.scrofulaceum 0.00 95.80 
M.gordonae 0.00 100.00 
M.fortuitum 0.00 · 2.60 
'M.chelonei · 0.00 27.'30 
Note : . 
a. MIC expressed in logarithmic value of 10 



















Table 49 : Susceptibility of different mycobacteria species against Mercury 
a M.I.C. (molar) 
Species -4 -3 -2 MEAN 
I · 
---------------- ----------------------------------------
MAl b 14.70 76.50 8.80 -3.06 
M.terrae complex 44.40 44.40 · 11.10 -3.33 
M.kansasii 12.50 87.50 0.00 -3.13 
M.scrofulaceum 29.20 62.50 8.30 -S.21 
M.gordonae 37.50 52.50 10.00 -3.28 
M. fortuitum · 7.70 74.50 12.80 -2.79 
M.chelonei 81 ~80 13.60 4.50 -3.77 
. Note: 
a. MIC expressed in logarithmic value of .1 0 
b. Figure in percentage 
\ 
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Table 50. Number of plasmids found in different Mycobacteria species 
Number of 
Number of plasmid organism 
Species 0 1 
. . 
2 :. 3 4 5 studied 0/0 
MAl 28 15 2 2 3 0 50 44.00 
M.terrae complex 20 2 2 . 1 0 0 25 20.00 
M.gordonae 4 8 11 12 9 1 45 91.11 
M.scrofulaceum 5 8 7 2 2 0 24 79.17 
M.fortuitum 26 11 8 1 2 0 48 45.83 
M.chelonae 24 2 1 0 0 0 27 11.11 
M.kansasii 8 1 0 0 0 0 9 11.11 
.' . 
Note: 
Figure indicated number of isolates 
0/0 indicates percentage of plasmid containing isolates 
\ . 
1'31 
Table 51 : t-value of mean MIC values on the 16 drugs tested against MAl 
between plasmid containing and non-plasmid containing isolates 
Drug pmean np mean t v 
Streptomycin 52.8 48 0 23 
Rifampicin . >64 >64 0 26 
Ethambutol 4.4 3.9 0.4 21 
Ethionamide 101.9 . >160 0 27 
Kanamycin 57.6 31.7 0 21 
Cycloserine 23.5 16.5 0 14 
Capreomycin 160 130.7 0 25 
Ofloxacin . >4.8 >4.8 0 26 
Ciprofloxacin >4.8 >4.8 0 25 -
Pefloxacin >4.8 . >4.8 0 11 
Fleroxacin >4.8 >4.8 0 12 
NetiImycin 51.2 52.3 o· 19 
Amikacin 47.5 53 0 19 
Gentamicin 45.9 44.7 0 26 
Isoniazid >1 >1 0 27 
pyrazinamide >100 >100 0 27 
Note: 
p mean : mean MIC of isolates that containing detectable plasmid(s) 
np mean: mean MIC of isolates that not containing detectable plasmid 
t : t-value 
v: degree of freedom 




















Table 52 : t-value of mean MIC values on the 16 drugs tested against M.fortuitum 
between plasmid containing and non-plasmid containing isolates 
Drug pmean ·np mean t v 
Streptomycin >64 >64 0 20 
Rifampicin >64 >64 0 20 
Ethambutol >5.6 >5.6 0 20 
Ethionamide >160 >160 0 19 
Kanamycin >64 >64 0 20 
. Cycloserine >56 >56 0 20 
Capreomycin 160 >160 0 18 
· Ofloxacin .2.02 4.55 0.07 11 
, . Ciprofloxacin 0.82 . 2.85 0.05 11 -
Pefloxacin >4.8 >4.8 0.08 · 18 
Fleroxacin >4.8 >4.8 0.06 20 
Netilmycin >64 >64 0.01 7 
Amikacin 23 37.33 0 11 
Gentamicin >64 >64 0 20 . 
Isoniazid >1 >1 0 20 
pyrazinamide >100 >100 0 20 
Note: 
p mean : mean MIC of isolates that containing detectable plasmid(s) 
np mean: ,mean M IC of isolates that not containing detectable plasmid 
t : t-value 
v . : degree of freedom . 




















Table 53 : t-value of mean MIC values on the 16 drugs tested against M.terrae complex 
between plasmid containing and non-plasmid containing isolates 
Drug pmean npmean t v 
Streptomycin >64 >64 0.01 11 
Rifampicin 16 >64 0.01 11 
Ethambutol 1.4 1.52 0.22 11 
Ethionamide 50 118.3 0 11 
Kanamycin >64 >64 0 11 
Cycloserine >56 >56 0 14 
Capreomycin >256 256 0 11 
·Ofloxacin >4.8 >4.8 0.06 11 
Ciprofloxacin >4.8 >4.8 0.05 11 . -
Pefloxacin >4.8 >4.8 0.04 11 
Fleroxacin >4.8 >4.8 0.04 11 
Netilmycin >64 >64 0.01 11 
Amikacin >64 >64 0 12 
Gentamicin >64 >64 0.01 11 
Isoniazid >1 >1 0 11 
pyrazinamide >100 :>100 0 11 
Note: 
p mean : mean MIC of isolates that containing detectable plasmid(s) 
np mean: m,ean MIC of isolates that not containing detectable plasmid 
t : t-value 
v : degree· of freedom 



















Table 54 : t-value of mean MIC values on cadmium between plasmid containing 
and non-plasmid containing isolates of mycobacteria 
Myco. species pmean np mean t v 
M.terrae complex -2.5 -1.7 1.22 7 
M.avium -2.82 -2.82 0 32 
M.gordonae -2.71 -3 0.05 37 
M. scrofulaceum -2.47 - -2.4 0.06 22 
M.kansasii -4 -2.4 2.43 6 
M. fortuitum -0.79 -1.2 0.02 13 
M.chelonae -1 -2.7 - -0.38 19 
-
Note: 
p mean : mean MIC of isolates that containing detectable plasmid(s) -
np mean: mean MIC of isolates that not containing detectable plasmid 
t : t-value 
v : degree of freedom 









Table 55 : ~-value of mean MIC values on lead between plasmid containing 
and non-plasmid containing isolates of mycobacteria 
Myco. species . p mean np mean t v p 
M.terrae complex ...;,1.5 -1.57 0.1 7 >0.4 
M.avium -1.59 -1.82 1.2 27 >0.4 
M.gordonae -2 -2 0 37 >0.4 
M.scrofulaceum -1.95 -2 0.24 18 >0.4 
M.kansasii -2 -1.86 0.44 6 >0.1 
M. fortuitum -1.07 -1 0.29 13 >0.4 
M.chelonae ~1 -1.3 0.34 18 ..- >0.25 
Note: 
p mean : mean MIC of isolatesthatcontaining detectable plasmid(s) 
np mean: mean MIC of isolates that not containing detectable plasmid 
t . : t-value 
v : degree of freedom 
p : p value 
\ 
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Table 56 : t-value of mean MIC values on mercury between plasmid containing and 
. non-plasmid containing isolates of mycobacteria 
Myco. species pmean np mean t v p 
M.terrae -4 -3.1 0.79 6 >0.1 
M.avium -2.82 -3.2 0.45 30 >0.25 
M.gordonae -3.26 -4.5 0.49 . 38 >0.25 
M.scrofulaceum -3.16 -3.4 0.15 22 >0.4 
M.kansasii -3 -3.1 0.44 6 >0.25 
M. fortuitum -2.89 -2.9 0 29 >0.4 
M.che/onae -2.5 -3.9 2.61 11 ~ <0.025 
Note: 
p mean : mean ty1IC of isolates that containing detectable plasmid(s) 
np mean: mean MIC of isolates that not containing detectable plasmid 
t : t-value 
v : degree of freedom 
p : p value 
\ 
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RT AREA tYPE AR/HT AREA% 
2.86 2.5547E+e7 SPB a.B74 98.558 . 
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Figure 3. Mass chromatogram generated by GC~MS showing 
the elution profile of saponification products extracted 

















































Figure 4. ,Gas chromatogram generated by GLC showing the 
elution profile of saponification 'products extracted 
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Figure 5. Ma~s chromatogram , generated by GC-MS showing 
the elution profile of saponification products extracted 
from Mycobacterium kansasii 
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Figure 6. Gas chromatogram generated by GLC showing the 
elution profile of saponification. products extracted 
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Figure 7. ,Mass chromatogram generated by GC-MS showing 
the elution profile of saponification products extracted 
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Figure 8. ~as chromatogram generated byGLC showing the 
elution profile of saponification products extracted 
from Mycobacterium marinum 
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Figure 9. Mass chromatogram generated by GC-MS showing 
the elution profile of saponification products extracted 
from Mycobacterium fortuitum. 
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Figure 10 . . Gas chromatogram generated by GLCshowing 
the elution profile of saponification products 
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Figure 11. Mass chromatogram generated by GC-MS showing 
:the elution profile of saponification products 
extracted from Mycobacterium chelonae 
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Figure 12 . .. Gas chromatogram generated by GLC showing 
the elution profile of ' saponification products 























Figure 13 . . All-groups scatterplot of slow growing non-
















* Group Centroids 
x----~--~----~----r----+----+---~----.X 
Out X X 
3 
4.0 
3 2 5 
2*2 5-
3 2:Jt 4 * 4 
22 324425 
.0 1112 5 44444 44 
1 1 *11 2 444:Jt4444 




. Out X X 
OU~---6-+. ~-_-4--i. ~-_-2--1. JI--. 6t---2-. ~+--4-.+-J -6-.-+-J -~' ut 
\ 
All-groups~catterplot 
11: indicates a 
group centroid 
Across: Function 1 
Down: Function 2 
Figure 14. All-groups scatterplot of rapid growing 
mycobacteria and Mycobacterium tuberculosis based on GC-










* Group Centroids 
X,----~--~~--~----~--_+----+_--~-----x 






3 333 3 
1 33*3 3 
1 3 33 33 
1 11 1*1111 3 2 233 
11 1 1 232 322 
1 ' 1 1 22*2 
1 222 
2 2 2 
X 
Ou ~·---6--1. ~"--' --4~·. ~+-' --2~' • +-K .;.,..... ---. . .-+-J "-2 .-+-~ -4 .-+~-6 -+. ~--..'\~u t 
\ 
All-groups Scatterplot 
* indicates a 
group cen troid ' . 
Across: Function 1 
Down: Function 2 
Figure 15. All-groups scatterplot of pigmented 
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Figure 16. All-groups scatterplot of slow growing non-
pigmented mycobacteria based on GLC analysis of 
saponification products. 
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Figure 17. All-groups scatterplot of rapid growing 
mycobacteria and Mycobacterium tuberculosis based on GLC 




I I ' 
I 





4 . M.vaccae 
. 5 M.chitae 
6' . M.diernhoferi 
·Group Centroids 
X----~--~~--~----~--_+----+_--~--~X 











22 * 1 







11 1*111 1 
1 11 11 1 
11 





* indicates a 
group centroid 
Across: Function 1 
Down: Function 2 
Figure 18. All-groups stacked histogram of 
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Figure 19. All-groups scatterplot ofpigmented 
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Figure 21. Percentage resistance of Mycobacterium 



























Ofloxacin Ciprofloxacin Pefloxacin Fferoxacin 
\ 
Figure 22. Percentage resistance of Mycobacterium 
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Figure 23. Cumulative percentage of Mycobacterium 
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Figure 24. Cumulative percentage of mycobacterium 

















































































































































































































































































































































































































































































Figure 25. Photograph showing agarose gel 
electrophoresis of mycobacterial DNA extracts obtained by 
the modified Kado and Lui method. 
Lane 1 · M.tuberculosis isolate (TB104) 
· 
. Lane 2 · BLANK ... 
· 
Lane 3 · M.tuberculosis isolate (TB103) 
· 




















M.tuberculosis isolate (TB98) 
· 




M.tuberculosis isolate (TB96) 
· 
. Lane 12 · M.gordonae isolate (P48) 
· 








M.tuberculosis isolate (TB93) 
· 
> · Chromsomal band 
· 
( r · Code of individual isolate 
· 
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1 2 3 4 5 678 9 10 11 12 13 14 15 
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Figure 26. Photograph showing ~garose gel 
electrophoresid of mycobacterial DNA extracts obtained , by 
the French Press procedure. 
Lane 1 : MA! isolate (AP103) 
Lane 2 :M.fortuitum isolate (AP106) 
Lane 3 : MA! isolate (AP98) 
Lane 4 : MAl isolate (AP89) 
Lane 5 : M.tuberculosis isolate (TB52) 
Lane 6 : M.terrae isolate (AP83) 
Lane 7 : M.kansasii isolate (AP48) 
Lane 8 : MA! isolate (AP31) 
Lane 9 : M.gordonae isolate (AP102) 
Lane 10 : M.tuberculosis isolate (TB306) 
Lane 11 : M.scrofulaceum isolate (AP112) 
Lane 12 : M.gordonae isolate (P32) 
Lane 13 : M.tuberculosis (H37) 
Lane 14 : E.coli plasmids, M.W. 37.6, 25.9 
Lane 15 : M.tuberculosis isolate (TB299) 
\ 
> : Chromosomal band 
( ): Code of individual isolate 
169, 
1 2 345 6 7 8 9 10 11 12 13 14 15 
\ 
Figure 27. ~hotograph showing agarose gel 
electrophoresis of mycobacter~al DNA extracts obtained 
by the spheroplast procedure (SP) and the modified Kado 
and Lui (MKL) method. 
. Lane 1 
· 










M.kansasii isolate (P17) - SP 
· 
Lane 4 · E.coli plasmid. MW 037.8 KB 
· 
Lane S M.kansasii isolate (P17) - SP 
Lane 6 M.kansasii isolate · (P17) - MKL 
Lane 7 M.tuberculosis isolate (TBS03) - SP 
Lane 8 
· 
M.tuberculosis isolate (TBS03) - SP 
· 
Lane 9 M.tuberculosis isolate (TBS03) - SP 
Lane 10 
· 
M.tuberculosis isolate (TBS03) MKL 
· 
Lane 11 M.tuberculosis H37Rv - SP 
Lane 12 
· 
M.tuberculosis H37Rv SP 
· 
Lane 13 M.tuberculosis H37Rv - SP 
Lane 14 · M.tuberculosis H37Rv - MKL 
· 
> · Chromosomal band \ 
· 
( ) Code of individual isolate 
,- ' . 






Figure 28. ,Photograph showing agarose gel 
electrophoresis of Mycobacterium tuberculosis DNA 
extracts obtained by the spheroplast procedure. 
Lane 1 · M.tuberculosis isolate (TB20) 
· 
Lane 2 · M.tuberculosis isolate (TB19) 
· 
M.tuberculosis isolate ' (TB18) -Lane 3 · 
· 




M.tuberculosis isolate (TB16) 
.' 
Lane 6 · M.tuberculosis isolate (TB15) 
· 
Lane 7 M.tuberculosis isolate (TBl4:) 
Lane 8 
· 




M.tuberculosis isolate (TB8) 
· 
Lane 10 M.tuberculosis isolate (TB7) 
Lane 11 
· 
M.tuberculosis isolate (TB5) 
· 
Lane 12 M.tuberculosis isolate (TB4) 
Lane 13 
· 
M.tuberculosis isolate (TB3) 
· 
C : Chromosomal band 
> : Plasmid, 
\ 
( ) Code of individual isolate 
111 
1 2 345 678 9 10 11 12 13 
\ 
Figure 29. Photograph showing agarose gel 
electrophoresis of atypical mycobacterial DNA extracts 
obtained by the Kado and Liu procedure. 
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MA! isolate (AP49) 
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Lane 12 MA! isolate (AP32) 






Other discrete 'bands are plasmid bands 
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Figure 30 • . Photograph showing agarose gel 
electrophoresis of Mycobacterium gordonae and 
Mycobacterium scrofulaceum DNA extracts obtained by the 
modified Kado and Liumethod. 
\ 
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Figure 31. Size of plasmids in pigmented species of 
slowly growing mycobacteria. 
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Figure 32. Size of plasmids in non-pigmented species 
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